Interview with the founder of BioBox on building a Biotech startup. We discuss their story, tips and tactics for startups. Check out the interview.

In discovery, sample preparation of biological specimens for advanced analytical and diagnostic testing is complex; and poorly controlled. The COVARIS Adaptive Focused Acoustics (AFA) technology platform, which delivers AFA-energetics, addresses the bottleneck between initial sample collection and downstream analysis across a variety of sample types. Join our COVARIS Webinar by to know more about how AFA Technology works. Webinar : AFA® Technology for High Quality Next-Generation Sequencing Data in FFPE Samples Date & Time : 25th Aug 2022 (Thursday) 10.00am-11.00am (GMT+8) Speaker : Dr Debadeep Bhattacharyya (Sr. Director, Marketing & Protein Market Development| Covaris, LLC, Woburn, MA, US)

In this Podcast, Rob Lalonde speaks with Nils Homer, founding partner at Fulcrum Genomics. Nils shares his unique perspectives on breaking into the bioinformatics industry, advances in technology and tools, and what to expect in the next three to five years.

https://irods.org/trirods Held on Wednesday, December 6, 2017, Todd Moughamer presented about the use of iRODS in Next Generation Sequence Data Management at Syngenta: DNA sequencing technology has evolved rapidly and resulted in data storage challenges for research organizations. Syngenta’s Next Generation Sequencing platform has been successful at getting data to researchers and analysts. However, there are opportunities to improve the users’ access to the data and the organization’s ability to manage and track data. Towards leveraging these opportunities, Syngenta has implemented a pilot of iRODS that integrates with their current processes and ways of working.

What is Next generation Sequencing Data Analysis? Subscribe & Stay Tuned: https://www.youtube.com/channel/UCN--_PeJb9zmB5YF_sHMtHw/videos For Facebook Updates:https://www.facebook.com/RASALSI/ Twitter: https://twitter.com/rasalsi?lang=en​ Join us on LinkedIN: https://www.linkedin.com/in/rasa-lsi-training-892b4497/ Follow us on Instagram: https://instagram.com/rasa_lifescience_informatics?igshid=1mwsctcdry8vn Next-generation sequencing (NGS) is a massively parallel sequencing technology that offers ultra-high throughput, scalability, and speed. The technology is used to determine the order of nucleotides in entire genomes or targeted regions of DNA or RNA. For more details: Visit us on: https://www.rasalsi.com/training-details/next-generation-sequencing-data-analysis-training-courses/ #ngsdataanalysis #ngs #livesessions #handsontraining #researchtraining #onlinetraining #savetime #researchpaper #RNAseq #CHIPseq #variantcaling #rasa #rasalsi

In this episode of the Futurum Tech Webcast, analysts Shelly Kramer and Ron Westfall discuss recent developments in the 5G and edge computing market, some recent research from IBM’s Institute for Business Value on how 5G and edge will help redefine the coming years, and key announcements out of MWC 2021 including Ericsson’s Google Cloud alliance, Qualcomm and Capgemini’s partnership, and how Netcracker, NEC, and AWS are demonstrating why the 5G Core (5GC) is ready for a larger role in supporting and scaling monetized 5G services. #ChadAndrews, #IBM, #IBMInstituteforBusinessValue, #Ericsson, #GoogleCloud, #EricssonandGoogleCloud, #QualcommandCapgemini, #Qualcomm, #Capgemini, #Netracker, #NECandAWSand5Gcore, #5Gcore, #5G, #MWC2021, #MWC, #MobileWorldCongress2021, #edgecomputing, #developmentsin5G, #IBMresearchon5Gandedge Futurum is an independent research, analysis, and advisory firm focused on digital innovation, market-disrupting technologies, and industry trends. Every day our analysts, researchers, and advisors help business leaders from around the world anticipate tectonic shifts in their industries and leverage disruptive innovation to either gain or maintain a competitive advantage in their markets. Subscribe: https://www.youtube.com/channel/UC7-rtz96bYgd2m4AhKtZFQw Get the latest tech news and opinions on: http://www.futurumresearch.com/ Follow Futurum Research on Facebook: https://www.facebook.com/futurumxyz Follow Futurum Research on Twitter: https://twitter.com/FuturumResearch Follow Futurum Research on Instagram: https://www.instagram.com/futurumresearch

One of the better rubber dome keyboards, with "Ergo Force Technology" variable weighting, but not an IBM Model M even though it looks similar at first glance. Fun Fact: The first Das Keyboard was identical to this except with a black paint job: https://www.youtube.com/watch?v=XYUW6eWES8s

Checking out the handcrafted IBM PC 40th Anniversary Limited Edition from Miniatua! It's a highly detailed 𝟙:𝟙𝟘 scale model replica of the 1981 5150 computer system with 5151 MDA monitor and dual floppy drives. And it even has a working TFT screen showing videos of software! Absolutely lovely. I purchased it here: https://www.miniatua.com/work/ibm5150anniversary/ 00:00 Introduction/Overview of the Model 06:26 Unboxing It! 12:21 Awestruck Admiration 16:28 Testing the Display 27:22 Musical Compilation/Collage Video Music at the end is 'Rising Sun' by DivKid

IBM Cognitive Test This video have been created to help you prepare for IBM Specific Gaming Aptitude test ,Also called Cognitive ability test. In IBM Gaming aptitude test ,they will be checking Sustained Attention, Accuracy, Response Inhibition, Speed, Cognitive Flexibility and Control, Multi-Tasking Ability and Memory. Types of games asked will be Shortcuts, Gridlock, Resemble, Numbubbles, Tally Up. Enjoy the learning with top Campus Recruitment Trainer Mr. Yanamala Suresh.

Block Ape Scissors uses simple mechanics for farmers to sharpen their tools before heading to the jungle to search for yield. https://www.blockapescissors.com/ Alpha Test: https://docs.google.com/forms/d/17aPjHtSCTh3hwbkXJ9k7_HAETR9wfCTaGmi2ktGVA0k Nickname Reservation: https://docs.google.com/forms/d/16Sjg1fv-_iV3xP6xN1LmH4CidDoEAiUvncFUMLBaEAs https://t.me/blockapescissors #BLOCKAPESCISSORS #NFTGAME #CRYPTOGAME - - - - - - - - - - WEEKLY CRYPTO GIVEAWAY: https://gleam.io/5rO9j/goalorious-weekly-crypto-giveaway-btc-eth-safemoon-doge-etc ** ONLY SUBSCRIBERS TO THE GOALORIOUS YOUTUBE CHANNEL ARE ELIGIBLE TO WIN ** 📱 Questions? Comments? Business Inquiries? 📧 Email Me: Goalorious@gmail.com THIS IS NOT FINANCIAL ADVICE. THIS IS NOT INVESTING STRATEGY. 💲 Get some Bitcoin with Coinbase https://www.coinbase.com/join/howlan_7u 💰 Earn Bitcoin when you sign up with Gemini https://gemini.com/share/568axppsg Thanks for watching! If you thought this video was helpful/informative/entertaining/awesome/okay then please subscribe to the channel. https://www.youtube.com/channel/UCATk5kugWqzwe80NIXwGIyQ?sub_confirmation=1 💼 Check out my Crypto Millionaire Maker - https://youtu.be/JSTPe2JzzXU 📈 Which of these altcoins is destined for the moon? https://youtu.be/LQyl-7afIYU 📚 BEFORE YOU BUY ANYTHING CHECK THIS: https://www.youtube.com/playlist?list=PLiH8WGj8__VAxcFsz-jzZj0HQVfCbvopf 📱 Follow Goalorious on Social Media https://www.Twitter.com/Goalorious https://www.Instagram.com/Goalorious https://www.Facebook.com/Goalorious ** DISCLAIMER ** CRYPTOASSETS ARE A HIGH RISK INVESTMENT. THE MARKET IS VOLATILE AND SIGNIFICANT PRICE CHANGES CAN OCCUR IN A SHORT PERIOD OF TIME. YOU COULD LOSE ALL OF YOUR INVESTMENT. DO NOT SPEND MORE MONEY THAN YOU CAN AFFORD TO LOSE. ⚠️ BE CAREFUL OF SCAMMERS WHO ARE IMPERSONATING ME IN THE COMMENTS ⚠️ Goalorious,block ape scissors,block ape scissors price,block ape scissors crypto,axie infinity,crypto,play to earn,nft,best crypto games,new crypto games 2021,earn crypto games,top crypto games 2021,top crypto games,crypto games ios,top blockchain games,earn crypto playing games,top 10 crypto games,best crypto games 2020,new crypto games,top 5 crypto games,crypto games 2021,the next axie infinity,nft games,blockchain games,crypto games,bas token

Richard Meszaros, Managing Director at Accenture, Anne Smith, Head of Automotive at IOTA, Divyesh Jadev, Manager of Applied Intelligence Research at IBM, and Dr. Bin Zhao, Co-founder of CPChain weigh in on the future of blockchain and mobility, relevant use cases, killer dApps, and the importance of cross-industry collaboration in blockchain research and standards development. This panel took place at MoCo Los Angeles on November 12, 2019.

For more videos and info visit: http://www.netcommunities.com/blog The new art & science of marketing This conference was the AOP's first event dedicated to business media. The speaker's are world class and there are workshops discussing profit improvement. If you want to stay at the forefront of all things B2B, Net Communities has selected the most beneficial lectures.

Try FreshBooks free, for 30 days, no credit card required at https://www.freshbooks.com/linus Save 10% and Free Worldwide Shipping at Ridge Wallet by using offer code LINUS at https://www.ridge.com/LINUS IBM invited us to do a facility tour showing off the mainframes they sell to high frequency trading customers and the like. You want to see wacky, custom hardware? This is it! Discuss on the forum: https://linustechtips.com/topic/1422880-i-tried-to-break-a-million-dollar-computer-ibm-tour/ ► GET MERCH: https://lttstore.com ► AFFILIATES, SPONSORS & REFERRALS: https://lmg.gg/sponsors ► PODCAST GEAR: https://lmg.gg/podcastgear ► SUPPORT US ON FLOATPLANE: https://www.floatplane.com/ FOLLOW US ELSEWHERE --------------------------------------------------- Twitter: https://twitter.com/linustech Facebook: http://www.facebook.com/LinusTech Instagram: https://www.instagram.com/linustech TikTok: https://www.tiktok.com/@linustech Twitch: https://www.twitch.tv/linustech MUSIC CREDIT --------------------------------------------------- Intro: Laszlo - Supernova Video Link: https://www.youtube.com/watch?v=PKfxmFU3lWY iTunes Download Link: https://itunes.apple.com/us/album/supernova/id936805712 Artist Link: https://soundcloud.com/laszlomusic Outro: Approaching Nirvana - Sugar High Video Link: https://www.youtube.com/watch?v=ngsGBSCDwcI Listen on Spotify: http://spoti.fi/UxWkUw Artist Link: http://www.youtube.com/approachingnirvana Intro animation by MBarek Abdelwassaa https://www.instagram.com/mbarek_abdel/ Monitor And Keyboard by vadimmihalkevich / CC BY 4.0 https://geni.us/PgGWp Mechanical RGB Keyboard by BigBrotherECE / CC BY 4.0 https://geni.us/mj6pHk4 Mouse Gamer free Model By Oscar Creativo / CC BY 4.0 https://geni.us/Ps3XfE CHAPTERS --------------------------------------------------- 0:00 Intro 1:16 What's a Z16? 1:55 Cooling 3:00 Power 3:40 Compute 6:00 Nutty Socket 9:18 Crazy VRMs 11:24 RAM like you've never seen it before 12:50 Cache work weird 15:00 now THIS is networking! 19:30 Welcome to the Patch Room 21:15 "my wife unit" 21:42 What's this for? 22:15 Price $$ 23:45 Outro

A pre-requisite for some of the software we want to unwrap and test out from Computer Reset. Check out installing and running advanced diagnostics to check out the cards readiness. And to our surprise, we discover it does detect in an expansion unit.

Donation: http://bit.ly/2FXei0Q Microsoft Windows Microsoft Windows is a group of several graphical operating system families, all of which are developed, marketed, and sold by Microsoft. Each family caters to a certain sector of the computing industry. Active Windows families include Windows NT and Windows Embedded; these may encompass subfamilies, e.g. Windows Embedded Compact (Windows CE) or Windows Server. Defunct Windows families include Windows 9x, Windows Mobile and Windows Phone. Microsoft introduced an operating environment named Windows on November 20, 1985, as a graphical operating system shell for MS-DOS in response to the growing interest in graphical user interfaces (GUIs).[3] Microsoft Windows came to dominate the world's personal computer (PC) market with over 90% market share, overtaking Mac OS, which had been introduced in 1984. Apple came to see Windows as an unfair encroachment on their innovation in GUI development as implemented on products such as the Lisa and Macintosh (eventually settled in court in Microsoft's favor in 1993). On PCs, Windows is still the most popular operating system. However, in 2014, Microsoft admitted losing the majority of the overall operating system market to Android,[4] because of the massive growth in sales of Android smartphones. In 2014, the number of Windows devices sold was less than 25% that of Android devices sold. This comparison however may not be fully relevant, as the two operating systems traditionally target different platforms. Still, numbers for server use of Windows (that are comparable to competitors) show one third market share, similar to that for end user use. As of October 2018, the most recent version of Windows for PCs, tablets, smartphones and embedded devices is Windows 10. The most recent versions for server computers is Windows Server 2019. A specialized version of Windows runs on the Xbox One video game console. Linux Tux the penguin Tux the penguin, mascot of Linux[1] Developer Community Linus Torvalds Written in C and others OS family Unix-like Working state Current Source model Open-source Initial release September 17, 1991; 27 years ago Marketing target Cloud computing, embedded devices, mainframe computers, mobile devices, personal computers, servers, supercomputers Available in Multilingual Platforms Alpha, ARC, ARM, C6x, H8/300, Hexagon, Itanium, m68k, Microblaze, MIPS, NDS32, Nios II, OpenRISC, PA-RISC, PowerPC, RISC-V, s390, SuperH, SPARC, Unicore32, x86, Xtensa Kernel type Monolithic Userland GNU[a] Default user interface Unix shell License GPLv2[7] and others (the name "Linux" is a trademark[b]) Official website www.kernel.org Linux (/ˈlɪnəks/ (About this soundlisten) LIN-əks)[9][10] is a family of free and open-source software operating systems based on the Linux kernel,[11] an operating system kernel first released on September 17, 1991 by Linus Torvalds.[12][13][14] Linux is typically packaged in a Linux distribution (or distro for short). Distributions include the Linux kernel and supporting system software and libraries, many of which are provided by the GNU Project. Many Linux distributions use the word "Linux" in their name, but the Free Software Foundation uses the name GNU/Linux to emphasize the importance of GNU software, causing some controversy Industrial engineering is an inter-disciplinary profession that is concerned with the optimization of complex processes, systems, or organizations by developing, improving and implementing integrated systems of people, money, knowledge, information, equipment, energy and materials[1]. Industrial engineers use specialized knowledge and skills in business administration, management, mathematics, physical sciences, social sciences and methods of engineering analysis and design to specify, predict, and evaluate the results obtained from systems or processes[1]. From these results, they are able to create new systems, processes or situations for the useful coordination of man, materials and machines and improve the quality and productivity of systems, physical or social[2][3]. Depending on the sub-specialties involved, industrial engineering may also overlap with, operations research, systems engineering, manufacturing engineering, production engineering, management science, management engineering, financial engineering, ergonomics or human factors engineering, safety engineering, or others, depending on the viewpoint or motives of the user. Even though its underlying concepts overlap considerably with certain business-oriented disciplines, such as operations management, Industrial engineering is a longstanding engineering discipline subject to (and eligible for) professional engineering licensure in most jurisdictions

IN THIS SESSION... Darío Gil, director of research at IBM talks through the urgency of accelerating progress and scaling the impact of science during the global COVID 19 pandemic. Twitter: https://twitter.com/ITU_AIForGood LinkedIn Page: https://www.linkedin.com/company/2651... LinkedIn Group: https://www.linkedin.com/groups/8567748 Instagram: https://www.instagram.com/aiforgood Facebook: https://www.facebook.com/AIforGood

This is an audio version of the Wikipedia Article: https://en.wikipedia.org/wiki/IBM_PC_compatible 00:02:11 1 Origins 00:07:03 2 Compatibility issues 00:07:13 2.1 Non-compatible MS-DOS computers 00:16:56 2.2 "Operationally Compatible" 00:22:38 3 The decreasing influence of IBM 00:30:03 4 Expandability 00:31:55 5 "IBM PC compatible" becomes "Wintel" 00:34:12 6 Design limitations and more compatibility issues 00:39:40 7 Challenges to Wintel domination 00:44:55 8 The IBM PC compatible today 00:47:59 9 See also Listening is a more natural way of learning, when compared to reading. Written language only began at around 3200 BC, but spoken language has existed long ago. Learning by listening is a great way to: - increases imagination and understanding - improves your listening skills - improves your own spoken accent - learn while on the move - reduce eye strain Now learn the vast amount of general knowledge available on Wikipedia through audio (audio article). You could even learn subconsciously by playing the audio while you are sleeping! If you are planning to listen a lot, you could try using a bone conduction headphone, or a standard speaker instead of an earphone. Listen on Google Assistant through Extra Audio: https://assistant.google.com/services/invoke/uid/0000001a130b3f91 Other Wikipedia audio articles at: https://www.youtube.com/results?search_query=wikipedia+tts Upload your own Wikipedia articles through: https://github.com/nodef/wikipedia-tts Speaking Rate: 0.761584605776648 Voice name: en-US-Wavenet-E "I cannot teach anybody anything, I can only make them think." - Socrates SUMMARY ======= IBM PC compatible computers are computers similar to the original IBM PC, XT, and AT, able to use the same software and expansion cards. Such computers used to be referred to as PC clones, or IBM clones. They duplicate almost exactly all the significant features of the PC architecture, facilitated by IBM's choice of commodity hardware components and various manufacturers' ability to reverse engineer the BIOS firmware using a "clean room design" technique. Columbia Data Products built the first clone of the IBM personal computer by a clean room implementation of its BIOS.Early IBM PC compatibles used the same computer bus as the original PC and AT models. The IBM AT compatible bus was later named the Industry Standard Architecture (ISA) bus by manufacturers of compatible computers. The term "IBM PC compatible" is now a historical description only, since IBM has ended its personal computer sales. Descendants of the IBM PC compatibles comprise the majority of personal computers on the market presently with the dominant operating system being Microsoft Windows, although interoperability with the bus structure and peripherals of the original PC architecture may be limited or non-existent. Some computers ran MS-DOS but had enough hardware differences that IBM compatible software could not be used; examples include slight differences in the memory map, serial ports or video hardware. Only the Macintosh kept significant market share without compatibility with the IBM PC.

Bill Rippon, Senior Network Engineer -- IBM Research Integrated Solutions

I’m sure you’ve all heard about IBM. They’re one of the pioneers of the PC industry, but nowadays, virtually no one uses IBM computers. Yet, IBM is still one of the largest companies in the world with a market cap of over $100 billion, so how does IBM even make money? Well, throughout IBM’s history, they were almost always a B2B company as opposed to a consumer brand. This is quite ironic given that they’re most well known for their PCs in the 1980s, but this was actually the exception for IBM, not the norm. After the dot-com bubble burst, IBM sold off its PC division to Lenovo and they started focusing on their B2B business once again. This consisted of producing server racks, networks, databases, and setting up cloud infrastructure. All of these background functions allowed IBM to rise to prominence once again, but with the rise of competition within these markets, IBM is struggling once again. Their revenues have nearly halved within the past 10 years and it’s not clear if they can compete against the juggernauts like Amazon and Microsoft. This video explains the rise, fall, rise again, and fall again of IBM. Discord Community: https://discord.gg/SJUNWNt Timestamps: 0:00 - The State Of IBM 2:20 - Founding IBM 5:25 - Industry Leader 8:36 - Painful Failure 11:29 - Resurrection Thumbnail Credit: https://bit.ly/3FH8uqJ Resources: https://pastebin.com/jAqDFJs2

Lots of large companies have set up innovation outposts in Silicon Valley, hoping to identify trends that can help their parent organizations avoid disruption. Jeffrey Welser shared best practices for running R&D labs in the Bay Area. Welser, a Vice President in IBM Research, oversees labs based in Almaden, Australia, China, and Japan. Watch more excerpts from the conversation or read the highlights: https://www.innovationleader.com/1286.article Get a ticket for our next Impact Event: https://www.innovationleader.com/events/upcoming-live-events/impact-2020

An in-depth overview on why the ThinkPad 760XL makes for great DOS gaming for a relatively low price and low footprint. Gaming showcase: 0:00 Intro 0:42 Specs & Features 2:46 Opening Hood 5:51 Battery LCD 6:21 Outer Finish 7:04 Battery Life 8:07 Processor Performance in Games 9:32 Sound Chip & Speakers for DOS 12:57 Port Selection 14:25 Comparison with ThinkPad 760XD 15:46 IBM Software Features 21:36 About the Gaming Experience 25:36 IBM TrackPoint Replacement Nubs 26:48 Conclusion 29:08 Doom 32:24 Skyroads 33:44 Tyrian 2000 36:13 Hexen 38:13 Wolfenstein 3D 40:54 The Secret of Monkey Island 43:06 Quake 44:29 Commander Keen in Goodbye, Galaxy! 46:35 Oil's Well BBISHOPPCM's video: https://www.youtube.com/watch?v=L5bkfjfhcC4

An overview of all sorts of monochrome graphical greatness! The IBM 5151 monitor, MDA graphics, Hercules graphics, emulated CGA, green/amber/white phosphor, text modes vs. addressable pixels, etc. Mmm, gotta love 80's computing! See my review of the IBM 5150 here: https://www.youtube.com/watch?v=8fkT0H-RQd4

Throwback Thursday way back to 1986! Say hi to CGA! Update! I finally beat this game. So glad to finally close this chapter of my life. Complete after ~40 years. Back when computers were very limited in color, and pixels are huge, my brothers I often play Round 42. 42 rounds of pixelated alien invaderesque fun! On our IBM PC-XT, with 4 color CGA monitor, most of the games are 4 colors: Black White, and either ugly red and green, or cyan and white. Somehow, this game got all of these colors! The game was hard, and the final enemy of each round moves ridiculously fast. Then we found that F2 fires the zapper weapon :P

A "spurt" sound isn't something you ever want to hear from your monitor... I knew I wasn't going to get away with leaving it shifting between blue and red for long, but I didn't think it would be this short. If I had seen the cap on the connector board for the CRT initially then I wouldn't have had to take the whole thing apart. But I kind of wanted to get an overview of what was going on inside anyway so I don't mind the extra work having been put in. But if yours blows a color cap you can easily avoid the most difficult part of removing the tube. I'm happy with how this turned out. I will be getting better capacitors later for it, but it isn't a rush. I think I made all the colors a bit dim on the adjustment on the back of the tube. That's probably why it seemed so much darker afterwards. Really, I should have done the calibrations at about 75% brightness. Oh well, it's not too difficult to get to that so I can always fix it later. Playlists of more stuff like this: Repairs: https://www.youtube.com/playlist?list=PLJVwF78cppBjvYSP5UdayY7te1vBthEv2 1980s: https://www.youtube.com/playlist?list=PLJVwF78cppBgCQCjbuyVorx-YC_HmxX4r Other Links Youtube: https://www.youtube.com/AkBKukU Github: https://github.com/AkBKukU Thingiverse: https://www.thingiverse.com/AkBKukU Patreon: https://www.patreon.com/AkBKukU Discord: https://discord.gg/E6xgGs6

Well it's working and booting off the CF drive to MS-DOS 6.22. Couldn't get a picture out of the CGA board's composite RCA output or DE9 CGA port ... but then I didn't RTFM either. Remaining plans: [1] make a cable from the floppy controller to the single, and original, 5.25" 360KB floppy drive [2] Replace the CGA board with a Graphics Gremlin board [3] Maybe make a DC37 floppy cable to run an external 3.5" drive So the final configuration is planned to be: Processors: NEC V20 with 8087 maths co-processor RAM: 640KB Storage: 1GB CF hard drive with 360KB 5.25" floppy & maybe external 720KB 3.5" floppy Video: CGA with VGA output connector I/O: DB25 serial, DB25 parallel, DA15 game Graphics Gremlin: https://github.com/schlae/graphics-gremlin

Wi-Fi Sheep is proud to be partnering with: http://www.pcbway.com The ONLY WAY for your custom printed circuit board requirements.. With PCBway.com new registered members get there first 10 PCBs free! Plus a $5 (US) welcome voucher when you join! Visit http://www.pcbway.com today! ======================================================= Wi-Fi Sheep Patreon: http://www.patreon.com/wifisheep Twitter: https://twitter.com/wifisheep | @wifisheep The PiTube direct module allows almost any vintage 8bit BBC Micro computer to connect to and harness the power of the Raspberry Pi. This allows for all sorts of amazing software to be used with the veteran system In this second follow up to our last video on the subject we take a in-depth look at some of the amazing software and even get PC -DOS games running in full CGA graphics mode!!! Don't forget to like and subscribe!!! Source Links: Stardot.org.uk - Master 512 DOS+ Software https://stardot.org.uk/forums/viewtopic.php?f=32&t=13918 CowsAreNotPurple.co.uk http://www.cowsarenotpurple.co.uk/bbccomputer/master512/ Video Links: Rob Coleman - Youtube: https://www.youtube.com/channel/UCeu2TKfJzju1L3JaF3Yuhog Event Links: Retro Computer Festival 2019 http://www.computinghistory.org.uk/det/53612/Retro-Computer-Festival-2019-7th-8th-September/ Milton Keynes Raspberry Jam https://mkraspberryjam.org/october-2019-tickets-available/ Music Credits - Tracks Used Kevin MacLeod - Incompetech.com https://incompetech.com/ Gocart Laser Groove Super Power Cool Dude AUDIONAUTIX.COM https://audionautix.com/ Metaphor Essence

Välkommen att delta på en öppen gästföreläsning om AI: "Language, Thinking and the Alchemy of Learning Machines: An introduction to the possibilities & challenges with Artificial Intelligence" med Patrick Couch , Business Developer focused on Artificial Intelligence & Cognitive Technologies IBM. Föreläsningen är startskottet för distansutbildningen "Tillämpad maskininlärning" vid Mittuniversitetet som startar den 20 januari 2021. Kursen ges helt på distans och kvartsfart vilket gör den lätt att kombinera med arbete. Du kan söka sent till kursen tom den 1 februari 2021. Välkommen! "Today, we live in a world which is in many regards digital first. Even seemingly non-digital events and phenomena such as the Corona pandemic, the US election and the democracy movement in Hong Kong are defined, understood and judged digitally first and only in an analog way secondly. Data and algorithms have come to inhabit a central place in our world and we now very much live in a world determined by the successes and failures of our technologies to understand us humans. Our social media feeds, our news feeds, our financial credibility, our entertainment, our shopping, our dating are all facilitated by data crunching algorithms doing their best to please. Obviously, this makes for great possibilities but also poses significant challenges. In this digitally defined world stands the developer, who like an alchemist conjures up new digital vistas for the rest of us to enter into, revel in and be challenged by. In the light of this, I will introduce the topic of artificial intelligence and the need to adress it intelligently."

Today I talk about my Win95/Win98 gaming rigs from back in the day, and discuss where this Aptiva fits as a 2020 replacement for that era. As mentioned in the video, I used to get my parts and machines from Novatech in the 90's, and they still seem to be going strong. I have no affiliation but if you're in the UK, check them out. https://www.novatech.co.uk/ I just think it's awesome than one of my old "go to" companies is still around. :) The Vintage Computer Club on facebook can be found here: https://www.facebook.com/groups/vintagecomputerclub/ Thanks again to: Matt for selling me such a great machine at an honest price. Aaron for help with the drivers. Mike for giving me Doom II and Descent II on disk. .....and no...it's NOT 4:3...I'm not imagining things!

Hosted by Fr. Robert Ballecer, SJ, Bryan Burnett IBM Rat Brain, PCIe SSD, and your questions! Records live every Thursday at 2:00pm Eastern / 11:00am Pacific / 18:00 UTC.

Welcome to the RogueTech Show! - This is our weekly show every Friday talking about technology, news of the week, and having some fun along the way... Pull up a chair, grab a coffee, and welcome... Amazon Prime Day - July 15th & 16th 6% Cash Back on Everything - https://amzn.to/2XE9gM4 Newegg Fantastech Sale - July 15th & 16th No Prime Required - https://pcdeal.tv/2GbAwLT Sources: https://www.reuters.com/article/us-usa-trump-cryptocurrency/trump-blasts-bitcoin-facebooks-libra-demands-they-face-banking-regulations-idUSKCN1U701I https://www.techpowerup.com/257269/asus-to-release-custom-navi-gpus-in-september https://www.techpowerup.com/257240/msi-scampers-to-launch-new-amd-400-series-motherboards-with-256mb-bios-chips https://wccftech.com/iphone-11-lineup-price-rumor/ https://wccftech.com/apple-2019-iphone-drop-shipments/ https://wccftech.com/ibms-purchase-of-red-hat-closes-today/ — Today's Special Promotion — BackBlaze https://pcdeal.tv/BackBlaze ^ 2 Week Free Trial, no Credit Card Required ———— — Shopping Links (Affiliate Links Support Us!) — Amazon https://pcdeal.tv/Amazon B&H https://pcdeal.tv/BHPhoto Newegg https://pcdeal.tv/NewEgg Walmart https://pcdeal.tv/Walmart EBay https://pcdeal.tv/EBay BackBlaze https://pcdeal.tv/BackBlaze EwinRacing https://pcdeal.tv/EWin - Use Code TECHDEALS for 30% Off Win 10 Pro - $15 - https://pcdeal.tv/Win10Pro - Use Code TD20 for 25% Off — Game Store Links — Humble https://pcdeal.tv/Humble Fanatical https://pcdeal.tv/Fanatical GreenManGaming https://pcdeal.tv/GMG — Follow / Support Us — Patreon - https://pcdeal.tv/Patreon Buy Me a Coffee - https://pcdeal.tv/BuyMeACoffee Twitch - https://pcdeal.tv/Twitch Twitter - https://pcdeal.tv/Twitter

CONF@42 - IBM - Phaedra Boinodiris - The Intersection of Cognitive Computing & Play, Making Data Science Actionable

Support the stream: https://streamlabs.com/cryptoverse » NASH SIGNUP https://nash.io/referrals?code=37iBzy » BRAVE BROWSER https://brave.com/cry662 » TELEGRAM CHANNEL https://t.me/cryptoverse_india » EXCHANGE » Kucoin: https://www.kucoin.com/?rcode=hx1yr3 » NEX https://nash.io/referrals?code=37iBzy » Bitmex https://www.bitmex.com/register/oOiuDA » Binance https://www.binance.com/?ref=13926552 » Giottus https://www.giottus.com/?refcode=RRK7WNS497 » Bitmax https://bitmax.io/#/register?inviteCode=QSAIH5C5 » SOCIAL MEDIA » Twitter: https://twitter.com/AshishS17228231 » Steemit: https://steemit.com/mgsc/@acryptoverse » HARDWARE WALLET » Ledger https://www.ledgerwallet.com/r/f624 » Trezor wallet https://goo.gl/4V78Tz » KeepKey hardware https://goo.gl/DhqRFD » TIPPIN ME https://tippin.me/@AshishS17228231 » CONTACT ME Gmail: ashish260686@gmail.com » BUY ME A COFFEE BTC » 1KUW53xtgXVnNAkaz6tZazY3jxPCHc2fYR ETH » 0xbF454be555f024816e4E854959363e6d85a20A84bff0856D -------------------------------------------------------------------------------- DISCLAIMER The information discussed on the Cryptoverse YouTube, Cryptoverse Podcast or other social media channels including but not limited to Twitter, Telegram chats, Instagram, facebook, website etc is not financial advice. This information is for educational, informational and entertainment purposes only. Any information and advice or investment strategies are thoughts and opinions only, relevant to accepted levels of risk tolerance of the writer, reviewer or narrator and their risk tolerance maybe different than yours. We are not responsible for your losses. Bitcoin and other cryptocurrencies are high-risk investments so please do your due diligence and consult the financial advisor before acting on any information provided. All rights reserved. -~-~~-~~~-~~-~- Please watch: "HOW TO STAKE VITE & VITEX VX TOKENS TUTORIAL, GET UPTO 0.5% STAKING REWARD DAILY IN HINDI" https://www.youtube.com/watch?v=wY5rzo0CC7M -~-~~-~~~-~~-~-

I bought this IBM 5155 Portable Personal Computer for spares and in non-working condition and I'm on a mission to get it to boot into an operating system. This part covers booting from a hard drive and trying out some games. Part 1 - https://youtu.be/FBv-3zpJfU0 Part 2 - https://youtu.be/YIyhGz4xq6I Part 3 - https://youtu.be/N4PjHLqVVzw Part 4 - This video Details of subjects covered are in the index below. Index: 0:00 - Introduction 0:41 - Booting from the hard drive (from my IBM 5160) 3:27 - Assembling the machine and a fault with the keyboard 5:41 - A look at the assembled machine and the temporary hard drive mounting 7:57 - Games 9:09 - Ms Pacman 12:32 - Railroad Tycoon 31:07 - Driller 37:08 - Conclusion and thanks

I was never aware of this computer "back in the day" ... I remember the IBM Convertible PC coming out with it's neat pop-up twin 3.5" floppy drives, but hadn't realised about this earlier Portable Personal Computer. It uses an earlier version of the IBM PC/XT (Model 5160) motherboard ... oh, and yes, the keyboard uses an RJ11 connector and not RJ45, duh. Got this sometime in 2018 for quite a good price - picked it up in Sydney so no shipping charges either - bonus! Ironically, it was "around the corner" from where we used to live (for ten years) before leaving Sydney for Port. From my earlier research, it appears to have an AST "SixPackPlus" memory expansion and serial I/O card, a standard CGA card, a hard drive plus an unknown card. I originally upgraded the BIOS to the latest available but then got stuck trying to get a CF drive and/or FlashFloppy drive to work. I may have also installed an NEC V20 and/or 8087 math co-processor. Maybe. Now that I've got it out again, first thing is to check what's lurking in the power supply before doing anything else. IBM Portable Personal Computer BIOS versions: http://minuszerodegrees.net/5160/bios/5160_bios_revisions.htm http://minuszerodegrees.net/bios/bios.htm

Got the power supply back together, re-installed the cards I needed: CGA with composite out, AST SixPakPlus memory expansion, floppy controller and XT-IDE (rev. 4 from Glitchworks). Left the HDD controller out. And ... it worked! Well, it POSTs a "601" error which I assume is because there's no floppy drives connected. I was surprised ... managed to get to GW-BASIC via the XT-IDE ROM boot. After some jumper fiddling, I managed to boot off the CF card. I'm using a 1GB Compact Flash card ("Dick Smith Electronics" branded!) that I know worked on my Amstrad PC1640 (using a Lo-Tech XT-IDE card). So it booted into MS-DOS 6.22 and was working fine. I loaded up my favourite game of all time ... The Ancient Art of War. Man, I played that game for hours ... along with The Ancient Art of War at Sea ... even managed to recover some campaigns I created on 5.25" floppies from back in the 90s (with references to now-ex-girlfriends, for some reason). Next - try to get the floppy drives working. Not really necessary as I can just load stuff onto the CF card, and even re-use the original HDD front panel & activity LED for the CF card ... let's see. Glitchworks XT-IDE Rev. 4 - mine's got "Slot 8" support and I'm using v1.1.5 of the XT-IDE BIOS (XUB): http://www.glitchwrks.com/2017/11/23/xt-ide-rev4 XT-IDE Rev. 4 summary: http://www.minuszerodegrees.net/xtide/rev_4/XT-IDE%20Rev%204%20-%20general.htm XT-IDE BIOS (XUB) versions: http://www.minuszerodegrees.net/xtide/XUB/XUB.htm

Nova Scotia, IBM Canada, the province's universities and the Nova Scotia Community College (NSCC) are joining forces to create hundreds of high-paying, long-term jobs, and ensure young Nova Scotians have the skills to succeed in them. IBM chose Nova Scotia as the best province to locate its only Global Delivery Centre in Canada.

Chatting with IBM Watson's VP Offering Management and Stategy, Mark Simpson about AI, machine learning and how businesses are using these and other technologies to better understand their customers today. Dan Costa - Host Weston Almond - Producer/Director Kirsten Cluthe - Producer Pete Haas - Social Media Manager Paul Maljak - Stills Photographer Jamie Lendino - Original Music In PCMag's Fast Forward video series, editor-in-chief Dan Costa talks to industry leaders about ground-breaking technology that will shape our future. Check out some of Dan's previous interviews here: https://goo.gl/rLPrCk PCMag.com is your ultimate destination for tech reviews and news. Subscribe to our videos here: https://goo.gl/JfBShr Like us on Facebook: https://www.facebook.com/PCMag Follow us on Twitter: https://twitter.com/PCMag Gawk at our photos on Instagram: https://www.instagram.com/pcmagofficial Get our latest tips and tricks on Pinterest: http://www.pinterest.com/pcmag

An off-the-cuff video of what I encountered an hour before the regular recording time - It just fell together from there. I look at the aspect of what I initially believed may be three bad drives - they are old and expected to fail. But what, let's see what we can swap out - I was glad to have another controller right at hand. Information on the hard drive controllers for the Model 50 and 50Z (integrated on the drive with DBA ESDI): https://ardent-tool.com/8550/8550_Controllers.html Help support this channel and content through Patreon: https://www.patreon.com/IBMMuseum

Donate: 18EQEiQBK1X2DyDL5Y18j78iw4NuNHoLej Save 20% off Amazon with Bitcoin at https://purse.io/ Featuring... Blake Anderson (https://twitter.com/bitcoinblake) Theo Goodman (https://twitter.com/theog__?lang=es) Tone Vays (https://twitter.com/Tone_LLT) and Thomas Hunt (https://twitter.com/MadBitcoins) THIS WEEK: ---------------------------- Bitcoin Payment Processor BitPay Loses $1.8M in Phishing Hack http://www.americanbanker.com/news/bank-technology/bitcoin-payment-processor-bitpay-loses-1m-in-phishing-hack-1076722-1.html IBM Adapts Bitcoin Technology for Smart Contracts http://www.wsj.com/articles/ibm-adapts-bitcoin-technology-for-smart-contracts-1442423444 NH House of Representatives to Vote on Bitcoin Bill http://www.coinbuzz.com/2015/09/17/nh-house-of-representatives-to-vote-on-bitcoin-bill/ Bitcoin Is Officially a Commodity, According to U.S. Regulator http://www.bloomberg.com/news/articles/2015-09-17/bitcoin-is-officially-a-commodity-according-to-u-s-regulator then Questions and Answers from the Audience! and Predictions! Please Subscribe to our Youtube Channel Would you like to support The Bitcoin Group? Donate Bitcoins to: 18EQEiQBK1X2DyDL5Y18j78iw4NuNHoLej bookmark our slightly empty homepage: http://www.thebitcoingroup.com/ Check us out on Twitter: https://twitter.com/thebitcoingroup or on Google+: https://plus.google.com/+Thebitcoingroup/

In der Oktober-Feedback-Ausgabe von echtgeld.tv sprechen Tobias und Christian über die Top 10 Aktienwünsche unserer Zuschauer & Mitglieder der echtgeld.tv Lounge. (www.echtgeld.tv) Alle Aktien in der Analyse und die Favoriten aus Eurer Auswahl seht Ihr im Video. #Aktienfeedback #Bayer #Uber *** ⭐️ Hinweis zum Sponsoring: Diese Sendung wird unterstützt durch Scalable Capital. Mehr zum Scalable Capital Broker-Depot mit Trading-Flatrate, inkl. Möglichkeit zur Kontoeröffnung: https://clickbiz.de/m-ref/egtvscalable * Ein mit * gekennzeichneter Link ist ein sogenannter Affiliate-Link. Kommt über einen derartigen Link ein Einkauf zustande, werden wir mit einer Provision beteiligt. Für Dich entstehen dabei keine Mehrkosten. Wo, wann und wie Du ein Produkt kaufst, bleibt natürlich Dir überlassen. *** Die einzelnen Themen und besprochenen Wertpapiere im Überblick: 0:00 Willkommen zu echtgeld.tv 01:36 Der Disclaimer mit Christian W. Röhl 03:10 Sponsorhinweis: Scalable mit verbessertem Sparplanangebot: https://clickbiz.de/m-ref/egtvscalable * 04:40 Bayer (WKN: BAY001) 15:41 Booking Holdings (WKN: A2JEXP) 23:02 Fraport (WKN: 577330) 31:38 IBM (WKN: 851399) 40:16 Markel (WKN:885036) 48:33 Novo Nordisk (WKN: A1XA8R) 55:16 OTIS (WKN: A2P1UZ) 1:01:10 Sea (WKN: A2H5LX) 1:08:48 Uber (WKN: A2PHHG) 1:21:25 Unilever (WKN: A0JMQ9) 1:29:22 Tobias & Christians Top-Pick aus Euren 10 Aktien-Wünschen 1:30:38 Drei Aktien ohne Besprechung: Gazprom (WKN: 903276), Lang & Schwarz (WKN: 645932) und wallstreet:online (WKN: A2GS60) *** ⚠️ Disclaimer: Keine Anlageberatung oder -empfehlung. Alle Angaben ohne Gewähr. Wertentwicklungen der Vergangenheit sind kein Indikator für zukünftige Wertentwicklung. Weitere ausführliche Informationen hierzu unter: http://www.echtgeld.tv/disclaimer/ *** Alle Informationen rund um https://echtgeld.tv/, Näheres zu Tobias Kramer und Christian W. Röhl, die Termine zur nächsten Live-Sendung, den Zugang zu allen Folien aus allen Sendungen sowie die Möglichkeit, Aktienwünsche zu platzieren, findest Du in der echtgeld.tv-Lounge unter https://www.echtgeld.tv/lounge/. 🎧 Eine Übersicht über unsere Kanäle findest Du hier: https://linktr.ee/echtgeldtv/

If you're asking, "How can I get my job done quicker with XPages?", this webinar will provide the answer. Mike McGarel and Paul Withers will compare and contrast commonly requested features using XPages and classic Notes/Domino techniques. You'll see how much smarter and faster XPages is, while providing the modern functionality that your users desire.

Inderpal Bhandari & Jesus Mantas of IBM sit down with hosts Jeff Frick & Peter Burris at the IBM Chief Data Officer Strategy Summit (Spring) in San Francisco, CA.

Today was Day 2 of CES 2021. GM reveals two concept vehicles from the Cadillac Halo portfolio—an autonomous vehicle and an electric vertical takeoff and landing aircraft; Razer shows off Project Hazel, a smart mask, and Project Brooklyn, a gaming chair; Terra Teat, CMO of JLab Audio, joins us to chat about the new Jbuds Jframes and their 2021 CES Innovation Award win; plus, Jeff Welser, VP of Exploratory Science & University Partnerships at IBM Research, stops by to talk about the announcement that IBM is number one in patents for 2020, AI, quantum computing, and opening it's portfolio of patents to help COVID-19 researchers. Follow Two Box Media on our site and social: http://www.twoboxmedia.com http://www.facebook.com/twoboxmedia http://www.instagram.com/twoboxmedia http://www.twitter.com/twoboxmedia Send us an email at info@twoboxmedia.com

Presented by Ulrich Weigand at GNU Tools Cauldron 2018 GCC and LLVM perform similar tasks, but the internal implementation is very different. As a maintainer of the IBM Z back end in both GCC and LLVM I've had the opportunity to become familiar with both worlds. In this talk, I'll give an overview of the current status of support for IBM Z processors in both GCC and LLVM, touching on differences in available feature sets and performance results. In addition, I'll be talking about my experience working in the context of both compiler frameworks. Where did I find GCC easier to work with, and where does LLVM have its advantages? The talk will look at these questions from a back-end perspective.

www.innotown.com Like InnoTown on Facebook: https://www.facebook.com/InnoTown Subscribe to our channel: https://www.youtube.com/user/InnoTown

Pastor Miki King Jan. 17, 2015 - Captured Live on Ustream at http://www.ustream.tv/channel/treasure-house-church-tv with the Ustream Mobile App

About this video: Mac Devine, CTO and Director of Cloudfirst Innovation at IBM, discusses the advantages of deploying a cloud-based platform made accessible via APIs. Devine explains that data is becoming the de-factor currency for facilitating business and stresses the importance of a clear mobile strategy to address the growing number of users with connected devices. Key Points • Deploy an API early and listen to feedback • The importance of speed and need to reshape culture • Importance of thinking mobile first • How to take advantage of this unprecedented convergence of trends • APIs have become the first business interaction point "You have to reach that tipping where you get enough usage, and you get enough value of that usage, that you start turning consumers into evangelists for that service." - Mac Devine, CTO and Director of Cloudfirst Innovation

THE TOWER OF THIEVES A foul wind is blowing in the kingdom of Pentawa. It blows through towns and villages with gales of blood and tempests of destruction. It calls itself 'The Blue Wind'. 'The Blue Wind' is a group of ruthless thieves who are casting a shadow of fear over the countryside. They have taken over the ruins of an old castle abandoned long ago under mysterious circumstances; its strange, forboding atmosphere seems somehow fitting to their purposes. A man, wounded in battle and nearly dead from hunger and thirst, has wandered into Pentawa looking for assistance. He tells of a narrow escape from the castle, and of a beautiful princess and many brave warriors held captive there. He also speaks of a vile demon and a dragon imprisoned for ages who may soon be free again. The king has issued an order for all Sorcerian adventurers worthy of the name to respond to this man's plea for help. 'Go forth in the name of your ancestors and rid the land of this evil that calls itself 'The Blue Wind'. GOAL An outlaw band is using a deserted castle as a base from which to raid nearby villages. They have captured the princess of a neighboring country and her company of fighters, who came to the castle on business of their own. There may be a dragon imprisoned under the castle. Infiltrate the Tower of Thieves, and rescue the princess and her warriors from this band of robbers, who may be more powerful than they seem. ITEMS VASE: Located on the altar in the chapel of the deserted castle. PASS: Several outlaws carry passes signed by Garok that allow them to go restricted places in the castle. GARATEEN: A holy sword in a silver scabbard. The blade is silver carved with sacred runes. RED BALL & BLUE BALL: These objects have something to do with opening some of the doors in the castle. PENDANT: A gold necklace with a large gemstone hanging from it. It possesses a strong protective magic. MONSTERS GAR: A ferocious fish that inhabits the lake under the castle. It has sharp teeth and powerful jaws. MAJOR DEMON: A shapechanging demon that likes to take human form. Cruel and very deadly. SHADOW DRAGON: The dragon has been imprisoned in a dark narrow cave for many years. Its wings have degenerated so that it can no longer fly, but its ability to breathe fire has not been diminished.

Learn how an investment in AI-Enabled Deep Learning cameras can help you optimize enterprise security, safety, business operations, and ROI for years to come. For more information, contact CG Moneta at admin@cgmoneta.com or Flagship Solutions Group at info@flagshipsg.com

In this episode of Classics, NDTV caught up with Mike Lawrie, the then strategist for IBM in August 2002. Mr Lawrie spoke about the global economic slowdown and economic scandals in the US. Watch full show: http://www.ndtv.com/video/player/talking-heads/talking-heads-mike-lawrie-of-ibm-aired-august-2002/305803

THE CURSED SHIP From the ship's log of the Maria Regina: 17th day, month of Dagonn. Fine. A good west wind. Good progress. Toward sunset, the cabin boy found Jacob's body in the forward hold. His throat had been cut. There were no witnesses. I can think of no-one who might want to kill Jacob -- he was well-liked among the crew. He had been ill the last few days, but it seems unlikely that he committed suicide. 24th day, month of Dagonn. Rain. I am afraid for my son. I don't like the idea of his being here on the ship, now that I'm certain that someone aboard is a murderer. I've tried to warn him to be cautious, but he wouldn't listen. Maybe my timing was bad; his pet macaw just disappeared. We will be putting in at Pentawa soon, and I want him to stay with his mother. Tensions are running high on the ship. The sailors are beginning to whisper that we are cursed. 3rd day, month of Hydra. Calm. When we dropped anchor in Pentawa Harbor, some people came on board asking for passage. They are adventurers, it seems, off to right some wrong somewhere. They treat it like some kind of sport. I offered them free passage in exchange for convincing my son to stay ashore when we leave. They may find this task harder than battling dragons. GOAL The ship Maria Regina is anchored in Pentawa Harbor. One of the sialors has been brutally murdered, and the rest of the crew is anxious and uneasy. The Captain's son refuses to go ashore to the safety of his mother's house. If the captain's dilemmas can be solved, he might be willing to give you passage aboard the Maria Regina to exotic ports where adventure abounds. ITEMS HATCH KEY: A key of simple design, it unlocks one of the ship's cargo holds. GOLD JAR: On its surface is engraved in ancient letters, "the one that is hard to let go." BLOOD STAINED AXE: No murder weapon has yet been found. Could this be it? AUGER: A common shipboard tool, used to make holes in barrels. MACAW: The captain's son's beloved pet. It was startled by a ship's rat and flew away. The boy is very upset. CABIN KEY: Key to unlock one of the sailor's private cabins. DESK KEY: This key opens a drawer in a desk somewhere on the ship. MONSTERS RAT: The rats aboard the ship have become very aggressive lately. GHOST: Spirits who seek out the living to rob them of life energy. SEAGULL: The seagulls are beginning to exhibit strange behavior, including attacking people. OWL: These owls, like the other animals around here, have begun to attack people. OAKROT: At first glance, this monster resembles the oak trees from which it evolved. (Note: Oakrot is not actually in any version of the game!) ARCHDEMON: This demon takes the form of a huge devil-face. Burning rays shoot forth from its mouth.

Governance is often seen as a dirty word. However, good governance processes can provide superior control and protection with minimal impact to the development team. In this session, we’ll cover good governance practices, from designing APIs to linting, validation, and control. With: - Chris Phillips, Master Inventor at IBM

A playthrough of Dynamix's third adventure title, The Adventures of Willy Beamish published by Dynamix/Sierra On-Line in 1991. Like Rise of the Dragon and Heart of China, Willy Beamish used the Dynamix Game Development System, which allowed programmers, artists, and writers to work simultaneously on the project within the same environment. It was the last adventure title to be directed by co-founder Jeff Tunnell before he left the company to form Jeff Tunnell Productions, most notable for creating The Incredible Machine series. A sequel, The Further Adventures of Willy Beamish, was rumored but never materialized. I'm playing the 1993 CD-ROM version with full voice acting and animated portrait close-ups Enjoy and please remember to visit my blog at https://www.retro365.blog where I post new articles every month. Intro 0:00 Day 1 3:38 Day 2 35:26 Day 3 1:06:08 Day 4 1:22:47

Composer(s): Chris Stevens, Jan Paul Moorhead, Don Latarski Year: 1991 Recorded from modified extracted midi files + SysEx from the game + Munt 1.2.0 Tracklist: ------------ 00 - Dynamix Jingle - 0:00:00 01 - Title - 0:00:10 02a - Carbuncle Assembly - 0:01:54 02b - Toupee Attack! - 0:02:44 03a - Dreaming of Nintari - 0:03:09 03b - Back to Reality - 0:03:49 03c - Glassy Class - 0:04:02 04 - Trespassing the Hallway - 0:05:55 05 - Principal's Room - 0:07:19 06 - Spider up The Wall - 0:09:07 07 - Busty the Nurse - 0:10:17 08 - School's Out! - 0:11:03 09 - The Beamish House - Day 1 - 0:12:01 10 - Kibbles 'n Grits - 0:14:00 11 - Beamish Backyard - 0:15:08 12 - Upstairs - Day 1 - 0:16:03 13 - Busy Train Room - 0:18:18 14 - Job Loss - 0:19:17 15a - TV - News Flash - 0:20:12 15b - TV - Slam Dunk Cola - 0:20:32 16a - Meanwhile - 0:21:40 16b - Foul Executives - 0:22:19 17a - Nintari Jingle - 0:23:34 17b - Monster Squad Theme - 0:24:02 18 - Nighty Night - 0:24:36 19a - Later On... - 0:25:08 19b - Waking up to a New Day - 0:26:08 20 - The Beamish House - Day 2 - 0:26:51 21 - Gordon's Conversation - 0:28:53 22a - TV - Frog Jump Competition - 0:30:08 22b - TV - TootSweet - 0:31:04 23 - Washing the Rover - 0:32:08 24 - Upstairs - Day 2 - 0:32:51 25 - Beautiful Suburbs - 0:35:02 26a - Tree Fortress - 0:36:19 26b - Horny Love - 0:37:39 27 - Slice 'o Life - 0:38:54 28 - Breaking Some Wind - 0:40:44 29 - Blow-up Spider - 0:42:33 30a - Jolly Park - 0:43:32 30b - Ultra Jump - 0:45:08 31 - Downtown - Day 2 - 0:45:30 32a - Babysitter From Hell! - 0:46:58 32b - Frantic Bat Chase - 0:47:37 32c - What Did Just Happen - 0:48:50 33 - The Beamish House - Day 3 - 0:49:34 34 - Corporate Lies - 0:51:52 35 - Upstairs - Day 3 - 0:53:10 36 - Tiffany's Fat Surprise - 0:55:32 37 - Downtown - Day 3 - 0:56:14 38 - Tiff the Punk - 0:57:29 39 - The Ferry Ride - Japanese Tourists - 0:58:08 40 - West-End Frumpton - 0:59:14 41 - TootSweet HQ - 1:00:26 42 - Outside Plumber's Union - 1:02:04 43 - Plumber's Rally - 1:03:37 44a - Golden Bowl - 1:04:23 44b - The Cripes - 1:05:11 45a - Gang Chase - 1:06:57 45b - Sudden Ninjas - 1:08:07 46 - Sushi Funtime - 1:09:38 47 - The Beamish House - Day 4 - 1:10:45 48 - Evil Vibes - 1:12:54 49 - Upstairs - Day 4 - 1:14:29 50 - Tiresome Interviews - 1:16:39 51 - Downtown - Day 4 - 1:18:07 52 - The Ferry Ride - Polka Overdose - 1:19:00 53 - Getting Ready for the Race - 1:20:13 54a - Junpin' Frogs - 1:21:29 54b - Frog Havoc - 1:21:52 55a - TootSweet Security - 1:22:38 55b - Horny is Caught! - 1:24:39 55c - Bailout - 1:24:50 56a - Sneaking in the Plumber's Union - 1:25:52 56b - Trapped! - 1:27:57 57 - Rigging Phone Calls - 1:29:05 58 - Creepy Mansion - 1:31:16 59a - Chef Childish's Kitchen - 1:34:12 59b - Setting the Frogs Free! - 1:35:21 60 - Frogs for the Rescue! - 1:36:15 61 - Underhanded Capture - 1:37:04 62a - Inside Golden Bowl - 1:37:50 62b - I Won the Lottery! - 1:39:02 63 - Sludgeworks Entrance - 1:40:14 64 - The Grand Chase - 1:42:24 65a - Treacherous Tram - 1:43:35 65b - Stanley Got Sacked! - 1:44:58 66 - Factory Monorail - 1:45:50 67 - Saving Dad - 1:47:18 68a - Hoooray! The Day is Saved! - 1:48:46 68b - Horny's Family - 1:50:17 69 - Game Over - Another Dimension - 1:50:29 69 - Game Over - Bonked by the Baddies - 1:51:03 69 - Game Over - Captured by The Bat - 1:51:54 69 - Game Over - Consequences #1 - 1:52:09 69 - Game Over - Consequences #2 - 1:54:27 69 - Game Over - Duffy Runaway - 1:55:40 69 - Game Over - Failed Drug Test - 1:57:18 69 - Game Over - Frumpton Carnival - 1:58:25 69 - Game Over - Hospital of Horrors - 1:59:30 69 - Game Over - Jailtime - 2:00:15 69 - Game Over - Military School - 2:01:01 69 - Game Over - Pastrami Quest - 2:01:43 69 - Game Over - Poorward - 2:02:14 69 - Game Over - Train and Mind Wreck - 2:03:14 UNK - Unused 01 - 2:04:13 UNK - Unused 02 - 2:04:21 UNK - Unused 03 - 2:05:22 UNK - Unused 04 - 2:06:20 UNK - Unused 05 - 2:07:33 UNK - Unused 06 - 2:08:27 UNK - Unused 07 - 2:09:28 UNK - Unused 08 - 2:10:44 UNK - Unused 09 - 2:12:05 UNK - Unused 10 - 2:14:00 UNK - Unused 11 - 2:15:46 Get the full soundtrack in FLAC: http://vengefulchip.tk/the-adventures-of-willy-beamish-ibm-pc-mt-32/ _________________________________________________________________ If you found this useful, please consider supporting me on Patreon! See this video for more details: https://youtube.com/watch?v=kfYDIV0fuBA Link to Patreon campaign: https://patreon.com/VengefulChip _________________________________________________________________ Disclaimer --------------- All rights reserved to the original authors/composers/publishers of this game (or game port). By posting this here I intend no malice to any of the aforementioned individuals/groups/companies. If you feel that your rights have been breached by posting this here please do let me know here: http://vengefulchip.tk/contact/ I'll take immediate action in removing the content from either the site, YouTube or both.

Composer(s): Chris Stevens, Jan Paul Moorhead, Don Latarski Year: 1991 Recorded on DosBox from modified SND files + NRS's FM Player Tracklist: ------------ 00 - Dynamix Jingle - 0:00:00 01 - Title - 0:00:10 02a - Carbuncle Assembly - 0:01:50 02b - Toupee Attack! - 0:02:36 03a - Dreaming of Nintari - 0:03:02 03b - Back to Reality - 0:03:30 03c - Glassy Class - 0:03:44 04 - Trespassing the Hallway - 0:05:06 05 - Principal's Room - 0:06:29 06 - Spider up The Wall - 0:08:18 07 - Busty the Nurse - 0:09:27 08 - School's Out! - 0:10:12 09 - The Beamish House - Day 1 - 0:11:16 10 - Kibbles 'n Grits - 0:13:24 11 - Beamish Backyard - 0:14:28 12 - Upstairs - Day 1 - 0:15:22 13 - Busy Train Room - 0:17:36 14 - Job Loss - 0:18:35 15a - TV - News Flash - 0:19:29 15b - TV - Slam Dunk Cola - 0:19:43 16a - Meanwhile - 0:20:50 16b - Foul Executives - 0:21:28 17a - Nintari Jingle - 0:22:37 17b - Monster Squad Theme - 0:23:03 18 - Nighty Night - 0:23:24 19a - Later On... - 0:23:57 19b - Waking up to a New Day - 0:24:38 20 - The Beamish House - Day 2 - 0:25:20 21 - Gordon's Conversation - 0:27:21 22a - TV - Frog Jump Competition - 0:28:34 22b - TV - TootSweet - 0:29:28 23 - Washing the Rover - 0:30:32 24 - Upstairs - Day 2 - 0:30:53 25 - Beautiful Suburbs - 0:33:01 26a - Tree Fortress - 0:34:18 26b - Horny Love - 0:35:37 27 - Slice 'o Life - 0:36:53 28 - Breaking Some Wind - 0:38:43 29 - Blow-up Spider - 0:40:30 30a - Jolly Park - 0:41:28 30b - Ultra Jump - 0:43:01 31 - Downtown - Day 1-2 - 0:43:21 32a - Babysitter From Hell! - 0:44:50 32b - Frantic Bat Chase - 0:45:27 32c - What Did Just Happen - 0:46:38 33 - The Beamish House - Day 3 - 0:47:21 34 - Corporate Lies - 0:49:39 35 - Upstairs - Day 3 - 0:50:55 36 - Tiffany's Fat Surprise - 0:53:18 37 - Downtown - Day 3 - 0:54:00 38 - Tiff the Punk - 0:55:13 39 - The Ferry Ride - Japanese Tourists - 0:55:36 40 - West-End Frumpton - 0:56:41 41 - TootSweet HQ - 0:58:09 42 - Outside Plumber's Union - 0:59:46 43 - Plumber's Rally - 1:01:17 44a - Golden Bowl - 1:02:02 44b - The Cripes - 1:02:54 45a - Gang Chase - 1:04:39 45b - Sudden Ninjas - 1:05:49 46 - Sushi Funtime - 1:07:18 47 - The Beamish House - Day 4 - 1:08:24 48 - Evil Vibes - 1:10:32 49 - Upstairs - Day 4 - 1:12:06 50 - Tiresome Interviews - 1:14:16 51 - Downtown - Day 4 - 1:15:45 52 - The Ferry Ride - Polka Overdose - 1:16:37 53 - Getting Ready for the Race - 1:17:48 54a - Junpin' Frogs - 1:19:04 54b - Frog Havoc - 1:19:50 55a - TootSweet Security - 1:20:34 55b - Horny is Caught! - 1:22:33 55c - Bailout - 1:22:42 56a - Sneaking in the Plumber's Union - 1:23:43 56b - Trapped! - 1:25:48 57 - Rigging Phone Calls - 1:26:55 58 - Creepy Mansion - 1:29:06 59a - Chef Childish's Kitchen - 1:31:35 59b - Setting the Frogs Free! - 1:32:45 60 - Frogs for the Rescue! - 1:33:24 61 - Underhanded Capture - 1:34:10 62a - Inside Golden Bowl - 1:34:55 62b - I Won the Lottery! - 1:36:05 63 - Sludgeworks Entrance - 1:37:15 64 - The Grand Chase - 1:39:29 65a - Treacherous Tram - 1:40:39 65b - Stanley Got Sacked! - 1:42:02 66 - Factory Monorail - 1:42:52 67 - Saving Dad - 1:44:18 68a - Hoooray! The Day is Saved! - 1:45:46 68b - Horny's Family - 1:46:58 69 - Game Over - Another Dimension - 1:47:07 69 - Game Over - Bonked by the Baddies - 1:47:32 69 - Game Over - Captured by The Bat - 1:48:21 69 - Game Over - Consequences #1 - 1:48:36 69 - Game Over - Consequences #2 - 1:50:53 69 - Game Over - Duffy Runaway - 1:52:04 69 - Game Over - Failed Drug Test - 1:53:43 69 - Game Over - Frumpton Carnival - 1:54:48 69 - Game Over - Hospital of Horrors - 1:55:52 69 - Game Over - Jailtime - 1:56:37 69 - Game Over - Military School - 1:57:22 69 - Game Over - Pastrami Quest - 1:58:04 69 - Game Over - Poorward - 1:58:33 69 - Game Over - Train and Mind Wreck - 1:59:32 UNK - Unused Tracks - 2:00:32 Get the full soundtrack in FLAC: http://vengefulchip.tk/the-adventures-of-willy-beamish-ibm-pc-soundblaster-pro-2/ _________________________________________________________________ If you found this useful, please consider supporting me on Patreon! See this video for more details: https://youtube.com/watch?v=kfYDIV0fuBA Link to Patreon campaign: https://patreon.com/VengefulChip _________________________________________________________________ Disclaimer --------------- All rights reserved to the original authors/composers/publishers of this game (or game port). By posting this here I intend no malice to any of the aforementioned individuals/groups/companies. If you feel that your rights have been breached by posting this here please do let me know here: http://vengefulchip.tk/contact/ I'll take immediate action in removing the content from either the site, YouTube or both.

See how IBM’s Watson and their Medical Minecraft mod, co-developed with high-school teachers and students, uses cognitive computing to explore the human body. Speaker: Porter Stowell (Serious Games, IBM)

This was a session from The Myositis Association's 2019 Annual Patient Conference in Minneapolis. Myositis is often a challenge to diagnose, sometimes taking years to distinguish from other disorders. This is especially true for those who live with sIBM, many of whom say they suspected something was wrong a decade or more before they were diagnosed. This session will discuss the signs and symptoms of IBM and the course this disease usually takes.

This is my complete keynote presentation at the IBM #newwaytowork event at CEBIT in Hannover, March 18, 2015. More details and PDF download at http://gerd.fm/ibmcebitstuff In this talk I cover topics such as big data, artificial intelligence, automation and humarithms vs algorithms. Thanks to IBM for making this video available to me! Gerd Leonhard Futurist, Author and Keynote Speaker Basel / Switzerland http://www.futuristgerd.com or www.gerdleonhard.de Please note: audio-only versions of many videos are being made available here: http://gerd.fm/gerdaudiofeed or on the web at http://www.futuretalks.com My vimeo channel is here: https://vimeo.com/gerdfuturist (you can also download all videos from here). Most of my books, presentations and slideshows are available via http://www.gerdcloud.com

Links: https://teksyndicate.com/videos/tek-0162-intel-ibm-cisco-etc-against-net-neutrality Music: http://bit.ly/Trk2ik, Merch: http://epicpants.com Game Deals: https://teksyndicate.com/gamedeals The Tek 0161 TOC: 0:00 - *INTRO* 0:09 - START 1:33 - Bring in Riker? Jonathan Frakes wants to direct 'Star Trek 3' 3:15 - Pirate Bay has been raided and taken down: Here's what we know, 'Each time police shut down Pirate Bay, we'll multiply other servers' - party head to RT, What comes after the Pirate Bay is a lot more important than whether it's up or down 7:31 - GCHQ follows NSA into paranoia -- Just as Julian Assange predicted 9:27 - SPONSOR SLOT 9:59 - Microsoft tells US: The world's servers are not yours for the taking 13:54 - Qualcomm, Intel, and others speak out against the Title II net neutrality 21:37 - HP will release a "revolutionary" new operating system in 2015 24:51 - Microsoft, Google, others threaten to sue Adblock Plus creator, Fraud from bots represents a loss of $6 billion in digital advertising 29:02 - It's here! Announcing Fedora 21 35:47 - Talking to dogs isn't so far-fetched: Researchers translate canine with computer science 37:43 - You've been using your monitor wrong this whole time 39:12 - British windfarms set new power production record 39:44 - Artificial skin that senses, and stretches, like the real thing 43:12 - 60,000 miles up: Space elevator could be built by 2035, says new study 44:35 - New 'high-entropy' alloy is as light as aluminium, as strong as titanium alloys 45:50 - Dean Hall starts recruiting for new game studio RocketWerkz 47:48 - iPhone 6 and iPhone6 Plus - Gamers 48:55 - Elite Dangerous Official Trailer (with added honesty) 50:32 - NetHack 53:24 - OUTRO, END ==== Join the community: https://teksyndicate.com/user/register You can create a new account or join using your google, steam, facebook, openID, twitter, linkedin, yahoo, etc. If you have questions, comments, suggestions, or if would like to use a portion of this video please email us: inbox@teksyndicate.com For marketing (sponsorship opportunities) inquiries email info@teksyndicate.com Social: Twitter: https://twitter.com/teksyndicate Logan's Twitter: https://twitter.com/Logan_RTW Facebook: https://www.facebook.com/teksyndicate

So it's too cold to make motorcycle vids so I'm inside messing with the pcs! I picked up this IBM Aptiva 2144-M51 and decided to make a Win 95/Dos gaming Pc! This will be a series of videos where I upgrade it to it's max potential! Thanks for watching!

Some of our community have requested some additional proof of our relationship with IBM. We hope this clarifies the partnership and our relationship with IBM.

This IBM Sterling B2B Integrator Tutorial talks about : 1. What is Adapter Service? 2. How to create a File Adapter Service? 3. Create a File System Adapter Service. 4. Create a Business Process 5. Deploy and Test a File System Adapter Service. For training in IBM Products please call us : Email : training.infinitedreams@gmail.com Visit Us: www.infinitedreams.org Call us : +1(309)205-4120

Curated crypto news focusing on key insights and relevant implications, with time stamps for each news! 00:14 BTC = $1M, IBM Head of Blockchain Predicts, IBM expand partnership beyond XLM to XRP, Bitcoin, stablecoin etc; 04:07 Germany to Launch Crypto Physical Futures; 07:34 Michigan Uni Endowment Ups Crypto Investment; 09:27 Pantera Capital Seals $130 Million for Third Crypto Fund; 14:07 Latin America’s Largest Investment Bank to Launch Own Security Token; 16:10 Stanford Researchers Develop Privacy Mechanism for Ethereum; 17:40 Third-Top Exchange OKEx Lists Ripple and Bitcoin Cash; 18:42 MyEtherWallet New Platform Converts Crypto to Fiat Without Know Your Customer Requirements; 20:20 ConsenSys Backs Ethereum-Based Unlisted Infrastructure Investment Startup Allinfra; 21:13 Binance Partners Zcoin in Blockchain-Powered School Lunch Campaign; 22:30 Anthony “Pomp” Pompliano Advices Warren Buffett to Buy Bitcoin; 24:12 Thai Parliament Approves Amendments Allowing Issuance of Tokenized Securities; 24:52 Korea Looks To US Decision on Bitcoin ETF; 26:40 UK Auction House to Sell Off $430K in Crypto Confiscated by Belgian Police. ---------------------------------------------------- Open An Account With Binance! https://www.binance.com/?ref=35677348 ---------------------------------------------------- Protect your crypto assets with LEDGER wallet: https://www.ledger.com?r=88a9903bf7db ---------------------------------------------------- Get ready for next RALLY - Spread awareness and knowledge of crypto around, especially to your ladies families, friends: www.queenakok.com

IBM internship 2021 | IBM Recruitment 2020 | 2021| 2022 Batch - job in IBM | IBM Hiring for Interns | Off campus internship | IBM internship for 2022 | internship in IBM | How to apply for internship in IBM| internship recruitment 2021 | off campus drive for 2021 2022 2020 | IBM Internship 2021, Hiring for Interns at IBM | IBM off campus recruitment 2021 | IBM recruitment 2021 how to apply | Any Branch Can Apply IBM Internship Apply Link: https://careers.ibm.com/job/12910179/ #ibminternship #ibmoffcampusdrive #howtogetinternshipinibm #internship #internship2021 #ibmrecruitment2021 #ittechiegirl #jobs #internship #recruitment2021 #offcampusdrive2021

Presenters: Rehan Qureshi, Advait Bopardikar, Ramey Ghabros Abstract: The next 5 years will see a wave of personalization, automation and enhanced citizen services enabled by artificial intelligence and cognitive solutions. Healthcare organizations have the potential and the imperative to embrace this transformation to improve service delivery and reduce costs. We invite you to attend a session hosted by the IBM Public Sector team. We will share our Roadmap to the Cognitive Enterprise, examples of RPA/Chatbots/Innovation Factories, use cases for government and health and discuss how to get there. Topics: AI Overview, Data Stewardship, Human Augmentation, Roadmap to Cognitive Enterprise, RPA, QA Automation, Visual Recognition, Chatbots, Innovation Factory

Welcome to Humanizing Software! A Livecast, dedicated to People Driven Tech. Each week we spotlight a technology leader that is Humanizing Software to solve real-world business challenges. This week, our host Andrew Tull, welcomes Allison Bacon, the Global Sales Executive for IBM Security, focused on the growth of Threat Management SaaS solutions. Allison is a trusted leader with a drive to achieve the impossible. After receiving her degree in Management Information Systems from the University of Arizona, she began her sales career at Dell Technologies, later moving to sales at IBM. 15 years later after the acquisition of Internet Security Systems, selling Intrusion Detection Systems (IDS) and Intrusion Prevention Systems (IPS) to Federal government accounts, she turned her focus on protecting and growing the recurring revenue stream across the IBM Security portfolio. Shifting her career to SaaS in 2015, Allison continues to drive Security SaaS revenue growth strategies. We can’t wait to dive into conversation with Allison. Join us LIVE for episode 15 of Humanizing Software! Powered by Tailwind Business Ventures. Join us as we embrace our "People First" mission. www.tailwindsw.com

A playthrough of the first Ringworld title, published by Tsunami in 1992. Tsunami was formed in 1991 by Edmond Heinbockel, former chief financial officer of Sierra On-Line. The company's first adventure title, Ringworld: Revenge of the Patriarch, was based on Larry Niven's Ringworld novel series. Ringworld was received with mediocre reviews at best and declared the 14th-worst computer game ever released by Computer Gaming World, nonetheless the title managed to spawn a sequel in 1994. Enjoy and please remember to visit my blog at https://www.retro365.blog where I post new articles every month.

http://www.retrogamervx.com Iprodeveloper forum thread: http://www.iprodeveloper.com/forums/aft/148384#6921401 Timeteam1982's channel: http://www.youtube.com/user/timeteam1982 EquallibriumGaming's channel: http://www.youtube.com/user/hwc1218 Center for Computing History Museum: http://www.computinghistory.org.uk/ Andy's channel: http://www.youtube.com/user/zombieAndy1979 I am also on Twitter too if you want more insanity in your life,have a website showing all my vids, my collection and a blog etc, and a Facebook group :o) Twitter : http://twitter.com/RetroGamerVX Facebook : Cut and paste this search "RetroGamerVX, Retro gaming" QUESTIONS: 1) Lets start with the cpu, although I've looked at IBM's system builders manual, they use their own codes in their so I cannot find the part numbers for either the cpu or tape drive. If anybody can help me with model numbers that would be suitable for this project, that would be useful :o) 2) With the tape drive, I've also been informed that you can use generic tape drives of the era to talk to this kind of set up and don't specifically need an IBM system, can you advise me on this as I am a complete novice. 3) With the hard drive, I believe I need about 1.2gb of storage. Can I use 9332's in this set up (I've been told they may be troublesome), or do I need another kind of storage solution (please advise). 4) And now for the largest problem.....the OS. I know that I will need os/400 for this, but is there a way to get a copy without sourcing from ibm (not a rich guy so no way I can afford it from them). I've also been told that I would need a copy specific to my hardware configuration. Is this true, and is there any way around this? 5) Ok, the other thing is, does anybody know of anywhere I can get the hardware for this without paying premium prices? If anybody knows, it would be a LOT of help :o) I hope you've enjoyed my video and any help you can give me with any of the points above, or any other thing you can think of will be very much appreciated :o)

Dr. Dhiraj Joshi, a 2007 Penn State alumni and current Senior Research Scientist at IBM Watson, speaks about his passion for artificial intelligence, multimedia analysis and multimedia data mining during Penn State Startup Week 2018.

A playthrough of Dynamix's second adventure title, Heart of China published by Dynamix/Sierra On-Line in 1991. Heart of China, inspired by big-screen adventures like Raiders of the Lost Ark and High Road to China, was developed using the Dynamix Game Development System, the same framework used in Rise of the Dragon released a year prior. The artwork used a mixture of digitized photos of live actors and hand-painted backgrounds. With a tight production budget, Dynamix had to recruit the cast of actors from the company's own employees and their families. The game's fantastic atmospheric settings, employing great color palettes and beautiful hand-drawn backgrounds looked amazing at the time and still do. The narrative while a bit on the cheesy and stereotypical side still makes for a great adventure. Enjoy and please remember to visit my blog at https://www.retro365.blog where I post new articles every month. Intro 0:00 Hong Kong 5:37 Chengdu 32:04 Kathmandu 50:14 Istanbul 1:17:32 The Orient Express 1:51:57 Paris 1:58:30

Support Me On Patreon! https://www.patreon.com/TheModernInvestor ---------------------------------------------------------------------------- Protect And Store Your Crypto With A Ledger Nano: https://www.ledger.com?r=8af3ed38d3b7 ----------------------------------------------------------------------------- Want To Send Me A Tip? Bitcoin Donations Address: 1BYhrLpntMYW97sd8K6fquTcr5MYwPAe2y Ripple (XRP) Donation Address: rsoKR5VHJx84oMTYbS7tWg7g5aFebYirVi Ethereum / KIN / OmiseGo Donation Address: 0x0e5f5CEFaA9A0713AB6D8F79E6679E22d86C21f6 ----------------------------------------------------------------------------- Open An Account With Binance! https://www.binance.com/?ref=22170588 ------------------------------------------------------------------------------ Buy Bitcoin And Ethereum With Fiat On Binance! https://www.binance.je/?ref=35009618 -------------------------------------------------------------------------------- Follow Me On Facebook ! https://www.facebook.com/TheModernInvestor https://www.youtube.com/channel/UC-5HLi3buMzdxjdTdic3Aig Follow Me On Twitter: https://twitter.com/ModernInvest ---------------------------------------------------------------------------------- Very Special Thanks To My Patreon Supporters: Professor Wally From Gunbot University RTC 2021 Forex Lens Inc Auspicious Agile & Blockchain Yet Another Nick Bitsource AML Solutions Chris Charles Roman Geber David Chosrova Stuart Niven Larry Gooch Tyler Winklevoss NBKrypto Steven Harper Ulf Fatman Josefsson Mohammad Tabbaa Brian Vaci Jeffrey Pete Mozar Cryptocurrency Logic Jonathan Robert Kraus Josh Gorcyca K9 Ytrup Crypto Jedi Truls Lee 3000 O. Tom Chhuong Kaneko Tomonori Sir Thomas11_11 Mike McCarty Crypto And Beer Shipmate ZEN Lunacy VV Nicola Kenny Mr. Smith Joey The Happy Farmer Damien Walker ---------------------------------------------------------------------------------- Photo Credit To: https://cdn.cryptopolitan.com/wp-content/uploads/2019/09/bitcoin-price-analysis-9th-september-2019.jpg

My Second Channel: https://www.youtube.com/channel/UCvXjP6h0_4CSBPVgHqfO-UA ---------------------------------------------------------------------------- Support Me On Patreon! https://www.patreon.com/TheModernInvestor ---------------------------------------------------------------------------- Protect And Store Your Crypto With A Ledger Nano: https://www.ledger.com?r=8af3ed38d3b7 ----------------------------------------------------------------------------- Want To Send Me A Tip? Bitcoin Donations Address: 1BYhrLpntMYW97sd8K6fquTcr5MYwPAe2y Ripple (XRP) Donation Address: rsoKR5VHJx84oMTYbS7tWg7g5aFebYirVi Ethereum / KIN / OmiseGo Donation Address: 0x0e5f5CEFaA9A0713AB6D8F79E6679E22d86C21f6 ----------------------------------------------------------------------------- Open An Account With Binance! https://www.binance.com/?ref=22170588 ------------------------------------------------------------------------------ Buy Bitcoin And Ethereum With Fiat On Binance! https://www.binance.je/?ref=35009618 -------------------------------------------------------------------------------- Follow Me On Facebook ! https://www.facebook.com/TheModernInvestor https://www.youtube.com/channel/UC-5HLi3buMzdxjdTdic3Aig Follow Me On Twitter: https://twitter.com/ModernInvest ---------------------------------------------------------------------------------- Very Special Thanks To My Patreon Supporters: Professor Wally From Gunbot University Digital Asset News Liam O'Cashidey Cory Stevens RTC 2021 Forex Lens Inc Auspicious Agile & Blockchain Yet Another Nick Bitsource AML Solutions Chris Charles Roman Geber David Chosrova Stuart Niven Larry Gooch Tyler Winklevoss NBKrypto Steven Harper Ulf Fatman Josefsson Mohammad Tabbaa Brian Vaci Jeffrey Pete Mozar Cryptocurrency Logic Jonathan Robert Kraus Josh Gorcyca K9 Ytrup Crypto Jedi Truls Lee 3000 O. Tom Chhuong Kaneko Tomonori Sir Thomas11_11 Mike McCarty Crypto And Beer Shipmate ZEN Lunacy VV Nicola Kenny Mr. Smith Joey The Happy Farmer Damien Walker ---------------------------------------------------------------------------------- Photo Credit To: https://bloximages.newyork1.vip.townnews.com/unionleader.com/content/tncms/assets/v3/editorial/1/b0/1b08ac24-6406-54db-b033-885570fad203/5e069f3a9de21.image.jpg?resize=400%2C268

theCUBE host Dave Vellante (@Dvellante) is joined by Ed Walsh from IBM for a CUBEConversation from our Boston studios #theCUBE #CUBEConversation https://siliconangle.com/2020/02/12/ibm-simplifies-storage-new-flashsystem-family/ IBM aims to simplify storage with new FlashSystem family IBM Corp. is trying to eliminate some of the complexity of data storage with a new family of flash storage products it introduced today to meet the needs of a large array of enterprises, including entry-level, midrange and high-end systems that extend to hybrid and multicloud environments. The new IBM FlashSystem is a family of products meant to address the varying storage requirements of organizations ranging from startups to large-scale enterprises. As the company explains, different businesses have different needs for their storage, with things such as performance, scalability, data services, functionality and high availability just some of the considerations. Traditionally storage vendors have solved this the easy way, simply by providing a massive range of different storage products for different purposes. That’s all well and good, but as the number of storage platforms an organization uses rises, so does the level of complexity they need to deal with. Complexity is never a good thing when it comes to information technology. In the case of storage, it means using different management systems for each storage platform, different ways to troubleshoot problems, different application programming interfaces in order to interact with those systems, different paths to the cloud and many other headaches. Add to that, most enterprises use several systems from multiple providers, adding to the headaches they need to deal with. The complexity means that organizations often have to delay the deployment of new storage technologies, while it also limits their flexibility and drives up costs. In an exclusive interview with Wikibon analyst Dave Vellante on SiliconANGLE’s mobile livestreaming studio theCUBE, Ed Walsh, IBM’s general manager of Storage and Software Defined Infrastructure, said the storage landscape has evolved into the complicated mess it is today because in the past, there was really no other way of doing things. “There’s always been a difference between high-end solution sets and low-end solution sets,” Walsh said. “Everything was based upon the features people needed, for example right availability, the right price points, features, functions, availability. It made sense that you had to have a unique thing. But because of the innovation we’ve driven, you no longer have to do that.” Perhaps the single-most important innovation with the new IBM FlashSystem family is that each system runs the same software stack. IBM Spectrum Virtualize provides the same “enterprise class data services” for entry-level all the way up to its high-end systems, while also enabling “nondisruptive data movement” and cloud and container deployments with supported storage, the company said. FlashSystem also provides consistent APIs for automating the provisioning and management of storage, supporting approaches including bare metal, virtualized, containerized and hybrid/multicloud workloads. “Our platforms are now one: It’s going to be one software and one API to manage,” Walsh said. “We’re going to do simplification without compromise we’re gonna give you what you need. You’re going to need an entry level packaging, midrange and high-end, but it’s going to be one software allows you to meet every single price requirement and functionality.” The new storage family comprises the IBM FlashSystem 9200, a high-end system for the most demanding of enterprise storage requirements; IBM FlashSystem 9200R, which is for customers that need a system that’s fully assembled, installed and configured by IBM’s engineers; IBM FlashSystem 7200, which provides hybrid and multi-cloud functionality for midrange enterprise deployments; and a number of entry-level offerings, including FlashSystem 5010, 5030 and 5100. IBM further promises “six nines” availability across all price points, with two- and three- site replication, cross-site high-availability configurations and the option for guaranteed 100% data availability. FlashSystem is managed in the cloud with IBM Storage Insights, which provides artificial intelligence-based analytics for insights into best practice recommendations plus 24/7 access to support when it’s needed. AI also powers the IBM EasyTier capability that helps to make sure the right data is placed in the right tier at the right time. With it, the “hottest” or most-used blocks of data move up the tiers as necessary when they’re more frequently accessed, while “cooler” blocks of data move down. ...

A belated look at an early Socket 478 all in one computer made by IBM. It has a 1.8 GHz CPU that almost certainly belongs to the Willamette family of Pentium 4 silicon. While it might sound completely stupid or fantastic to consider contacting a TV show production company in search of computer parts, there are some production companies that have auctioned off old props. I was, after all, slightly desperate to find a power supply. Luckily, a power supply showed up on eBay for a price that I was willing to pay! The rest, as they say, is history...

Support Me On Patreon! https://www.patreon.com/TheModernInvestor ---------------------------------------------------------------------------- Protect And Store Your Crypto With A Ledger Nano: https://www.ledger.com?r=8af3ed38d3b7 ----------------------------------------------------------------------------- Want To Send Me A Tip? Bitcoin Donations Address: 1BYhrLpntMYW97sd8K6fquTcr5MYwPAe2y Ripple (XRP) Donation Address: rsoKR5VHJx84oMTYbS7tWg7g5aFebYirVi Ethereum / KIN / OmiseGo Donation Address: 0x0e5f5CEFaA9A0713AB6D8F79E6679E22d86C21f6 ----------------------------------------------------------------------------- Open An Account With Binance! https://www.binance.com/?ref=22170588 ------------------------------------------------------------------------------ Buy Bitcoin And Ethereum With Fiat On Binance! https://www.binance.je/?ref=35009618 -------------------------------------------------------------------------------- Follow Me On Facebook ! https://www.facebook.com/TheModernInvestor https://www.youtube.com/channel/UC-5HLi3buMzdxjdTdic3Aig Follow Me On Twitter: https://twitter.com/ModernInvest ---------------------------------------------------------------------------------- Very Special Thanks To My Patreon Supporters: Professor Wally From Gunbot University RTC 2021 Forex Lens Inc Auspicious Agile & Blockchain Yet Another Nick Bitsource AML Solutions Chris Charles Roman Geber David Chosrova Stuart Niven Larry Gooch Tyler Winklevoss NBKrypto Steven Harper Ulf Fatman Josefsson Mohammad Tabbaa Brian Vaci Jeffrey Pete Mozar Cryptocurrency Logic Jonathan Robert Kraus Josh Gorcyca K9 Ytrup Crypto Jedi Truls Lee 3000 O. Tom Chhuong Kaneko Tomonori Sir Thomas11_11 Mike McCarty Crypto And Beer Shipmate ZEN Lunacy VV Nicola Kenny Mr. Smith Joey The Happy Farmer Damien Walker ---------------------------------------------------------------------------------- Photo Credit To: https://s.thestreet.com/files/tsc/v2008/photos/contrib/uploads/32e19443-91d0-11e9-b9f3-3764b2918254.png

Mr. Peter Hofstee, professor from TU Delft & Research staff member at IBM has delivered his presentation on In-Memory Big Data for Power10 a personal perspective.

In this video we go over the epic rise and fall of technology giant IBM. IBM was once America's most innovative tech companies but they were eventually surpassed by Apple, Microsoft, Google, and others. We go into a deep dive of IBM's history and their future outlook. Join our free Discord Server: https://discord.gg/VBd6cA4jUt Check out our second channel WSM Research: https://www.youtube.com/channel/UCQUOscigSQWCVG8m-ZC8wiw #WallStreetMillenial

Learn how to size your POWER9 Power Systems servers with confidence. Download the IBM i capacity planning guide today! https://www.helpsystems.com/cta/how-right-size-power9-capacity-configuration Imagine your boss says it’s time to migrate to the cloud. He’s excited about being the first on the block, plus it would look good to eliminate the capital expenditure (capex) of your on-prem data center. So, what’s it going to take? Many businesses are looking to migrate IBM Power workloads to one or more providers in the growing IBM i cloud market. But moving to the cloud isn’t just an infrastructure refresh exercise—you’re re-engineering the underlying architecture of your core business applications. Watch this recorded webinar where our IBM i experts walk you through the performance configurations you should consider before moving to the cloud, including I/O, CPW, disk, memory, and more! You’ll also learn: - How to identify workloads best suited for cloud - Sizing techniques designed to avoid excessive charges - How to streamline data replication during the transition period - Data security risks and how to avoid them - Licensing considerations Moving to the cloud is a big project, and one thing’s for sure: once you’re there, you don’t want to be forced to move back due to performance issues. That’s why it pays to plan carefully for the cloud. Watch now!

Patreon: https://www.patreon.com/alexandercobb Buy & Trade Crypto: https://www.bitrue.com/activity/landing?inviteCode=ZQGQQZ Merch: https://teespring.com/stores/XRP-Merchandise Ledger Nano S, Keep Your Cryptocurrency Safe! (offline storage) https://www.ledgerwallet.com/r/20ef?path=/products/ledger-nano-s&tracker=MY_TRACKER I AM IN NO WAY A FINANCIAL ADVISOR AND AM NOT GIVING FINANCIAL ADVICE I AM STRICTLY GIVING MY OPINION Thank you for watching! If you like to donate xrp to support the channel Deposit Address: rLHzPsX6oXkzU2qL12kHCH8G8cnZv1rBJh Destination Tag: 424786908 Twitter https://twitter.com/AlexCobb_ Keywords: Ripple News , XRP news, Ripple XRP News, Bitcoin Cryptocurrency

Cybersecurity is a topic that continues to dominate the IT landscape. Cyber resilience is critical to enabling business acceleration by preparing for, responding to, and recovering from cyber threats like ransomware. Organizations of all sizes should be aware of how to leverage IBM data and cyber resilient storage if they want to have a comprehensive cybersecurity strategy without breaking the bank. Please join us for a webinar event by industry leaders Storcom and IBM. IBM's Tony Pearson and Storcom's Dave Kluger will guide you through the following features of IBM' Storage's cyber resilient storage to ensure your organization's most valuable asset (your data!) is protected: -Role-Based Access Control (RBAC) and Multi-Tenancy -Encryption and Secure Erase -Data Immutability -IBM Safeguarded Copy for Logical Corruption Protection

Dave Vellante talks with Eric Herzog & Sam Werner, IBM, in this edition of CUBEconversations

I just picked up this IBM 5160 the other day and I'm really excited to try and get it going! I am stunned the HDD is still working in this computer! Who knows when it was last powered on, if the head was parked, or how roughly it's been treated. I'll probably make this computer my dual monitor system once I move a color card into it since its 8 ISA slots make it easier to waste one on a weird setup like that. I'm definitely leaving the original HDD in there though and am going to use it. It's just to cool to pull and replace with an XT-IDE. Playlists of more stuff like this: Computers: https://www.youtube.com/playlist?list=PLJVwF78cppBjb_EinOYA2QnzaNwryOvfE Repairs: https://www.youtube.com/playlist?list=PLJVwF78cppBjvYSP5UdayY7te1vBthEv2 1980s: https://www.youtube.com/playlist?list=PLJVwF78cppBgCQCjbuyVorx-YC_HmxX4r Other Links Youtube: https://www.youtube.com/AkBKukU Github: https://github.com/AkBKukU Thingiverse: https://www.thingiverse.com/AkBKukU Patreon: https://www.patreon.com/AkBKukU Discord: https://discord.gg/E6xgGs6

Innovation is essential for survival in today's competitive world. However, with the rapid advances in client expectations, and enabling technologies, how can we inspire the right innovations? How can we maximise the effectiveness and productivity of innovation activities? In this talk Rashik shares his perspectives on these questions.

This video demonstrates some shareware and public domain titles for the IBM PC (and compatibles) from my personal 5.25" floppy disk collection from the late 1980s. The PC in this video is a Commodore PC 10-S (Siemens 8088 running at 4.77MHz and 640kB of memory) + monochrome monitor (the IBM 5151). 00:00 Bootup 00:21 R.J.Grafe's 1983 "Centipede" 03:15 Sheng-Chung's 1983 "Pango" 05:04 Vince Bly's "Bricks" 06:25 "TIC-TAC-TOE" 07:53 Columbia Data Products, Inc's "Space Commanders" 09:46 Wally Wasinger's 1986 "Night Fire" 12:04 Williams Electronics/Atari 1982/1983 "Joust" 13:48 "Global Thermonuclear War!" 15:06 Max Headroom demo 15:39 John D.Price and PC Research, Inc. 1983/1984 "3-Demon" 19:15 "Pyramid-Power" 20:22 "PC Golf" 23:01 Peter Adams' 1984 "Flightmare" 28:17 Elven Software Company's 1986 "Round 42" 33:09 Dave Baskin's "Bouncing Babies" 36:06 Pinball 37:28 Don Phillip Gibson's 1985 MS-DOS adaption of "Monopoly" 40:40 Bill Seiler's 1985 "Spacewar" For more information about displaying color graphics on a text-only monochrome monitor: https://youtu.be/e1xgHZpiONk

AVD PRODUCTIONMobile: +84986339943 (contact for booking video shoot) Website: http://avdproduction.net Copyright ©avdproduction #avdproduction #livestream #webinar #fpt #ibm

A playthrough of Broken Sword: The Shadow of the Templars, published by Virgin Interactive in 1996. The Shadow of the Templar, known as Circle of Blood in the US was the first title in the Broken Sword series and was co-written and directed by Charles Cecil, and developed by his Revolution Software. It was acclaimed by critics, who praised the game's story, art direction, musical score, voice acting, and writing, and would over the next handful of years sell around a million copies. This is part 1 of 2. Enjoy and please remember to visit my blog at https://www.retro365.blog where I post new articles every month. Intro 0:00 Paris 2:19 Lochmarne 1:39:05 Paris 2:24:34

A playthrough of Broken Sword: The Shadow of the Templars, published by Virgin Interactive in 1996. The Shadow of the Templar, known as Circle of Blood in the US was the first title in the Broken Sword series and was co-written and directed by Charles Cecil, and developed by his Revolution Software. It was acclaimed by critics, who praised the game's story, art direction, musical score, voice acting, and writing, and would over the next handful of years sell around a million copies. This is part 2 of 2. Enjoy and please remember to visit my blog at https://www.retro365.blog where I post new articles every month. Marib 0:00 Paris 38:31 Spain 47:51 Paris 1:05:50 Spain 1:34:45 Paris 1:55:03 Scottland 1:59:23 Credits 2:26:08

Composer: Thierry Carron Year: 1995 Recorded from the game's CDDA tracks Tracklist: ------------ 01 - Spring - 00:00 02 - Summer - 04:25 03 - Autumn - 08:54 04 - Winter - 12:01 05 - News Flash - 16:24 06 - Economic Upturn - 16:34 07 - Christmas - 19:36 08 - Game Over - 19:50 UN - Unknown #1 - 20:05 UN - Unknown #2 - 20:15 UN - Unknown #3 - 20:31 Get the full soundtrack in FLAC: http://vengefulchip.tk/aiv-network-c-e-o-ibm-pc-cdda/ _________________________________________________________________ If you found this useful, please consider supporting me on Patreon! See this video for more details: https://youtube.com/watch?v=kfYDIV0fuBA Link to Patreon campaign: https://patreon.com/VengefulChip _________________________________________________________________ Disclaimer --------------- All rights reserved to the original authors/composers/publishers of this game (or game port). By posting this here I intend no malice to any of the aforementioned individuals/groups/companies. If you feel that your rights have been breached by posting this here please do let me know here: http://vengefulchip.tk/contact/ I'll take immediate action in removing the content from either the site, YouTube or both.

Leading global tech analysts Patrick Moorhead (Moor Insights & Strategy) and Daniel Newman (Futurum Research) are front and center on The Six Five analyzing the tech industry's biggest news each and every week and also conducting interviews with tech industry "insiders" on a regular basis. The Six Five represents six (6) handpicked topics that will be covered for five (5) minutes each. Welcome to this week’s edition of “The 6-5.” I’m Patrick Moorhead with Moor Insights & Strategy, co-host, joined by Daniel Newman with Futurum Research. On this week’s show we will be talking: 4:50 HPE Storage Day 12:35 Google, NVIDIA, Qualcomm Spar on AI Domination 20:47 IBM Z Goes Rack Mount 26:24 Italy Bans OpenAI 35:31 Dell Announces Qualcomm-Based Laptop 41:11 Intel Announces 13th Gen vPro HPE Storage Day https://twitter.com/PatrickMoorhead/status/1643299409046777857?s=20 https://twitter.com/danielnewmanUV/status/1643349288511057924?s=20 Google, NVIDIA, Qualcomm Spar on AI Domination https://www.cnbc.com/2023/04/05/google-reveals-its-newest-ai-supercomputer-claims-it-beats-nvidia-.html https://twitter.com/PatrickMoorhead/status/1643792415457783808?s=20 IBM Z Goes Rack Mount https://twitter.com/PatrickMoorhead/status/1643292276800512015?s=20 Italy Bans OpenAI https://apnews.com/article/chatgpt-openai-data-privacy-italy-1e3f070ca86ec234cae4d08ac8443879 https://futurumresearch.com/research-notes/italy-dpa-announces-ban-of-openais-chatgpt-will-other-eu-countries-follow-suit/ Dell Announces Qualcomm-Based Laptop https://futurumresearch.com/research-notes/dells-first-windows-on-arm-architecture-laptop-is-using-the-qualcomm-snapdragon-8cx-gen-2-soc/ Intel Announces 13th Gen vPro https://futurumresearch.com/research-notes/intel-announces-vpro-platform-with-13th-gen-processors/ Disclaimer: This show is for information and entertainment purposes only. While we will discuss publicly traded companies on this show. The contents of this show should not be taken as investment advice.

Gravitas showcasing - AI BOT demo (www.gravitas.ai) on IBM.TV- 29 April 2020 "Startup Wednesday- Tech Day" #Startups #Business #techday #Innovations #smallbusiness #mediumbusiness #funding #growthstory #investors #innovations #unicorns #worldnews #ibmtv

Coursera: Introduction to Artificial Intelligence (AI-IBM) Quiz Answers | All Week Quiz and Answers. Course:- Introduction to Artificial Intelligence Organization- IBM Platform- Coursera In This Video:- Introduction to Artificial Intelligence Coursera Week 1 Quiz Answers Introduction to Artificial Intelligence Coursera Week 2 Quiz Answers Introduction to Artificial Intelligence Coursera Week 3 Quiz Answers Introduction to Artificial Intelligence Coursera Week 4 Final Assignment Part 1 Solutions LINK- http://courserasolutions.info/2020/07/18/introduction-to-artificial-intelligence-ai-week-4-final-assignment-part-one-solution/ Introduction to Artificial Intelligence Coursera Week 4 Final Assignment Part 2 Solutions LINK- http://courserasolutions.info/2020/07/18/introduction-to-artificial-intelligence-ai-by-ibm-peer-graded-assignment-final-assignment-part-two-solutions/ #IBM #INTRODUCTION_TO_AI #COURSERA

IBM Computer History - Restored from an ancient VHS copy, this vintage IBM made film shows IBM’s impressive growth and product versatility from 1919 to about 1970. Film starts at the year 1919, and shows the celebration at Endicott, New York, the "birthplace" of IBM. At that time the company was still called CTR for “Computing-Tabulating-Recording Company.” CTR was renamed "International Business Machines" in 1924. This black & white film runs 22 minutes. Provided for educational and historical purposes; Computer History Archives Project. (Film courtesy of IBM Archives.) Highlights: 0:19 IBM Convention, Endicott New York in 1919 0:22 Vertical card sorter; Tabulating Machines 01:10 IBM Executive School, sales staff 01:50 Thomas J. Watson, Sr., 1924 IBM named 02:05 The 100 percent club, Atlantic City 02:40 Old numerical printers 05:15 First IBM 600 Multiplier machine 1929 06:00 Thomas J. Watson, Sr., speaks *** 06:51 Thomas J. Watson, Jr., speaks 09:28 World War II influences 10:32 War ends; 10:34 Digital Computing Machine production 13:55 Random Access devices 17:00 IBM System/360 18:00 1964 IBM day at New York World’s Fair 18:20 President Eisenhower with Mr. Watson 19:00 Business and scientific applications & more Endicott New York is perhaps best known as the "Birthplace of IBM". The Computing-Tabulating-Recording Company (CTR) was founded in Endicott on June 16, 1911, through the consolidation of the International Time Recording Company (ITR), The Tabulating Machine Company, Computing Scale Company, and Bundy Time Recording. Stats: original view count 13,740

0:00 Intro 01:17 Ginni's book - Good Power 03:39 Ginni on becoming IBM's CEO 07:00 The Infinite Game 10:00 Ginni's childhood adversity 14:23 Is hard work controversial? 18:34 Obstacles, risk-taking, victimhood 24:30 Should you fit in or should you stand out? 33:54 What should change and what should endure 42:53 Chat GPT, the state of AI 46:44 Lessons from Ginni's book We had the privilege to host Ginni Rometty, former IBM CEO and author of the thought-provoking book "Good Power." Join us as she shares her remarkable journey of overcoming adversities and navigating her illustrious career in the tech industry. From her early struggles to becoming a trailblazing leader, Ginni Rometty's story is one of resilience, determination, and the transformative power of embracing challenges. Discover her insights on leadership, innovation, and the pursuit of good power in this inspiring conversation. 🎙️ The Aarthi and Sriram Show: Aarthi Ramamurthy and Sriram Krishnan host conversations with leading builders, and CEOs and reveal what it takes to make it to the inside. 🔊 Listen On Spotify: https://open.spotify.com/show/2CuAlPdZGhV1yxShmdcYh6?si=1f1ef00601ce46d0 🔊 Listen on Apple Podcasts:https://podcasts.apple.com/us/podcast/aarthi-and-srirams-good-time-show/id1624345213 📕 Subscribe on Substack: https://substack.com/profile/113921987-aarthi-and-srirams-podcast 📷 Follow Sriram on Instagram: https://www.instagram.com/sriramk/ 🐦 Follow Sriram On Twitter: https://twitter.com/sriramk?s=20 📷 Follow Aarthi On Instagram: https://www.instagram.com/aarthir/?hl=en 🐦Follow Aarthi On Twitter: https://twitter.com/aarthir

Download Dashlane for free on your first device by clicking here: http://bit.ly/2PxXthI and automatically get a 30 day free trial of premium! No credit card required at signup! Thanks to Dashlane for sponsoring this video! ● Liked this video? Subscribe for more: http://mjd.yt/subscribe It's a better DOS than DOS, and a better Windows than Windows! Today, we're gonna be trying to install the last version of IBM's OS/2 operating system on the $5 Windows 98 PC. Let's s̶t̶a̶r̶t warp! ● Join our forum community: https://osforums.net ● Gear I use to make these videos: https://www.kit.co/mjd Camera: https://amzn.to/2K5ia3D Tripod (mine is discontinued): https://amzn.to/2IcI6YM Smaller Tripod: https://amzn.to/2UfLAk9 Microphone: https://amzn.to/2XrmZdb Editing Software (Premiere): https://amzn.to/2uKtrvN Thumbnail Editor (Photoshop): https://amzn.to/2WRxvqj ● Affiliate Links Get a FREE 30-DAY TRIAL of Amazon Prime: https://amzn.to/2xVmMB3 Get 2 FREE Audiobooks with Audible: https://amzn.to/2Ovylse Amazon: https://www.amazon.com/?tag=teammjd-20 Save 10% on PDF Expert: https://pdfexpert.com/store?code=MICHAEL_MJD ● Follow Me: Twitter: https://twitter.com/mjdtweets Instagram: http://instagram.com/mjdmichael Facebook: https://facebook.com/mjdmichael ● Music/Credits: Background Music: http://www.incompetech.com & YouTube Audio Library Outro Music: Silent Partner - Bet On It Source: YouTube Audio Library Amazon Affiliate Notice: I am a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com. All Amazon links that I provide will use my affiliate code with Amazon. Some materials in this video are used under Section 107 of the Copyright Act of 1976, which allows "fair use" for purposes such as criticism, commenting, news reporting, teaching, and research. #MichaelMJD #OS2 #Windows98

https://archive.org/details/IBMOS2Warp4Collection twitter: @sahajsarup Instagram: @ric_96 My Gaming Channel: https://www.youtube.com/channel/UC9ybuwuWuMGnEzDLH3Qc77A blog: geektillithertz.com/wordpress

Remembering the old operating system IBM OS / 2 Warp Server of "Big Blue". IBM probably with this brand new system tried again to conquer the general public, however, although OS/2 failed in the consumer market it triumphed in sectors that already dominated. Thanks to the robustness and the reliability demonstrated este OS is still used today in 2020 and since the early 90s in many ATMs and in large institutions such as the New York City Subway.

OS/2 Warp 3 Installed on the IBM PC 340 I got an Ensoniq Audio PCI card and a USB adapter card installed in the IBM Personal Computer 340. After that, I install OS/2 Warp 3 Connect. It took a bit longer than I anticipated, so I will have to do other installments of the video series showing off OS/2 Warp in more detail and applying fixpacks and drivers. Have fun.

Wherein we gesticulate wildly at an old computer, fail to play SimCity and look at Japanese web pages from 25 years ago. Marugoto CD: https://archive.org/details/OS2Shareware-MarugotoCD-Japanese

Oh baby! I remember when these sweet 486 computers were the most powerful thing. Also, research is apparently for chumps. Ouch. We're trying out Software Inc! It's sort of The Sims meets a tycoon game (which one is already sort of the other). I've been aching to find a way out of the basement and pretend to be super successful, so this seems like a good fit. --- Connections --- Twitch: http://twitch.tv/maladapted See it here first, or wait until I chop it up. Steak is steak, right? Twitter: http://twitter.com/MaladaptedX --- About The Software Inc. --- Run your own software company! Construct and design buildings for optimal working conditions. Hire people to design and release software, so you can defeat the simulated competition and take over their businesses. Manage and educate your employees to make sure they are skilled and satisfied with their job. Software Inc. is currently in early access for Windows, Linux and Mac. Developer: https://softwareinc.coredumping.com/ Steam: http://store.steampowered.com/app/362620/Software_Inc/

Our New Product Introduction (NPI) process for Cell & Gene Therapies manufacturing provides a standardized, systematic approach to tech transfers, manufacturing and Pre-Approval Inspection readiness to reliably take your therapy to commercialization.

For decades, patients have been using self-administration devices to deliver medications through subcutaneous injections, with the insulin pen injector as perhaps the most well-known of these devices. Recent developments in drug delivery and device technology are significantly expanding the market. Ian Thomson from Ypsomed and Roman Mathias from Lonza discuss the market trends in injectable delivery devices, their manufacturing process, and their future in sustainable pharma. Injectable devices offer various benefits, including improved convenience, accuracy, and safety, allowing for precise dosing while reducing the need for hospital visits.

Cell and gene therapies have the potential to revolutionize the treatment of rare genetic diseases, cancer, and neurodegenerative disorders. These therapies involve extracting cells or genetic material from a patient or donor, altering them and then re-injecting them back into the patient to provide a highly personalized treatment. However, the manufacturing process for these therapies is complex and expensive. To increase the availability of these therapies, the industry is making strides in scaling up the manufacturing process to reduce costs. In this episode, we take a deep dive into manufacturing cell and gene therapies with Lonza expert Behnam Ahmadian Baghbaderani, executive director of Cell and Gene Therapy Process Development.

Cell and gene therapies are generating hope for many patients where there are no other options to provide meaningful benefits. At Lonza in Cell & Gene Technologies (CGT) we are proud to be enabling and accelerating their global delivery through our sites in the US, Europe and Asia. With products and services for allogeneic and autologous cell therapies, as well as viral vector gene therapies, we are working on novel therapies using cutting-edge technology to push boundaries in healthcare. Join our team and make a Meaningful Difference with us: https://www.lonza.com/careers/job-search

Our premium liquid-filled dosage form offerings combine proprietary capsule design and fusion technology with innovative ingredient delivery systems, allowing you to create highly functional and uniquely experiential nutraceutical products.

In 2016 Lonza established its Drug Product Services (DPS) to realize this supply chain model for its partners and clients. Since then the DPS has grown to a workforce of over 250 experienced experts focused on safety, efficacy and quality. To ensure that Lonza’s pharmaceuticals perform as expected in real-world situations, the DPS team simulates the entire administration process until certain the patient will receive the correct dose of the highest quality.

A Welcome Virus: Cracking the Viral Code for the Battle Against Cancer Chairman and founder of PsiVac, Prof. Ghassan Alusi, and the chief operating officer, Imad Mardini, discuss how the company’s proprietary oncolytic virus platform offers new hope for cancer patients. During a time when everyone actively fears viruses (especially THE virus) and their mutations, it is only cancer cells that have cause to worry about oncolytic viruses, and rightly so. These mutated viruses are administered directly into a tumor. Once inside, they crack open the tumor’s cells in a process known as lysing that provokes a strong response from the body’s immune system, which has, until then, ignored the cancerous cells. What’s more, the therapy’s attack doesn’t stop at a single tumor. The replicating and lysing viruses release previously hidden tumor-associated antigens (TAAs) that alert the immune system about cancer cells to attack all over the body. The body’s own immune system then goes on to destroy previously unrecognized tumors far removed from the initial injection point. The biotech company PsiVac advances this technology even further by creating a treatment platform that transforms the adenovirus, aka the common cold, into an especially powerful oncolytic virus. A precision modification in the virus’s DNA improves its efficiency against cancer cells while making it harmless to other cells, rendering the treatment at once more effective and safer for patients. “Now that the technologies of other forms of immunotherapy are gaining ground, and as cancer remains a major cause of mortality, we now understand there is a huge need for oncolytic viral therapy,” says Prof. Alusi, whose company has planned to start Phase 1 clinical trials later this year. Unlike other immunotherapies, such as patient-centric CAR T-cell therapy, oncolytic viruses can be made in relatively large quantities once their efficacy and safety have been proved. Curious to Know More? In the first episode of the new season of the podcast A View On, host Martina Ribar Hestericová discusses the current state of oncolytic viruses and their promising applications with Prof. Ghassan Alusi and Imad Mardini. KEY TERMS: Cell lysing is the process of breaking down a cell’s membrane, destroying the cell and releasing its contents into the body. If an oncolytic virus lyses a cell, it releases replicated versions of itself as well as antigens helpful in the immune system’s fight against a tumor. Tumor-associated antigens (TAAs) are released once a cancer cell is lysed, setting the previously dormant immune system into action. The release of TAAs means that the tumor is no longer successfully hiding from the immune system, and the body can begin to fight the disease by its own means. The cytotoxicity of a virus is the extent to which a virus attacks and destroys cells, often an undesirable event. However, with oncolytic viruses, this cytotoxicity works in a patient’s favor, thanks to gene editing, by being specifically designed to attack cancer cells. An agnostic oncolytic virus targets not only one or a group of cancers but is effective against all malignant solid palpable tumors. PsiVac’s modified adenovirus has proven agnostic so far, making it a powerful weapon in the fight against cancer.

Delivering Personalized Therapies: Streamlining the Supply Chain for a New Generation of Treatments In this episode, we speak with Amy DuRoss, Co-Founder and Chief Executive Officer of Vineti, about the challenges facing "just-in-time" manufacturing and delivery of personalized therapies—and the solutions her digital startup provides. According to Amy DuRoss, the COVID-19 vaccine distribution has exposed existing deficiencies in the entire pharmaceutical supply chain. This situation echoes, albeit on a far smaller scale, the distribution complexities of delivering cell and gene therapies (CGT). Unlike more traditional treatments, CGT requires the extraction of live cells from a patient or donor to then be delivered to a manufacturer and make it back to the patient in a timely manner. Her company Vineti "introduces a new level of fidelity, control, and transparency" into the personalized drug delivery process, streamlining CGT distribution through a novel digital orchestration platform. Based on an astute understanding of the behavior of care providers, specialized couriers and CGT manufacturers, her company has developed a software infrastructure that supports this exponentially complex delivery process. By facilitating Good Manufacturing Principles for all required stakeholders in the advanced therapy process, the Vineti platform ensures regulatory compliance and maintains both Chain of Identity and Chain of Custody from cell collection to manufacturer and back to the patient. Curious to Know More? Take a listen to this episode of A View On: Streamlining Cell and Gene Therapy Manufacturing to learn more about Vineti. At the end of the discussion, as a bonus for our listeners, Amy DuRoss offers insight into some of the difficulties encountered in the COVID vaccine rollout, and how it parallels the complexity of the supply chain for CGT. KEY TERMS: Personalized medicine and therapies, such as cell and gene therapies (CGT), treat patients on a much more individualized basis. They require an unprecedented level of automation and navigation because the materials used to prepare the end product are raw cells originating from a donor or a patient. Good Manufacturing Principles (or Practices), GMP for short, are practices that ensure adherence to the guidelines put forth by regulatory agencies. They apply to any manufacturing industry but reach an unparalleled level of complexity in CGT production due to the implication of health care providers in the cell extraction and donor matching processes. A digital orchestration platform such as Vineti's uses the power of data management and user experience design to organize and execute an effective supply chain system in the face of exceptional complexity and strict regulations. Chains of Identity and Custody in the pharmaceutical supply chain are the cornerstones of regulatory compliance, whereby each step in the process and each individual involved is transparently identifiable in order to reduce the risk of contamination and to eliminate fraud. With CGT production, the process of extracting the raw materials for the treatment directly from the patient or donor multiplies the Chains of Identity and Custody, exponentially increasing the supply chain complexity.

Artificial Intelligence and Life Sciences: The Dawning of a Digital Revolution in Pharma Manufacturing Dr. Loubna Bouarfa, CEO of OKRA.ai, and Stephan Rosenberger, Lonza's Head of Digital Transformation, discuss how AI is currently transforming the pharma industry. Machine learning is an essential subset of the vast field of Artificial Intelligence, in which computer programs aim to mimic human intelligence. Machine learning is at work in many of the algorithms that impact our daily lives, from suggesting new songs we might like to targeting ads. These algorithms learn from large data sets similarly to how a child learns during the early stages of development. As the algorithm matures from child to teenager to adult, it refines its own functioning by learning from its errors and through help from humans, much like we do. This powerful way of programming is making tsunamis across nearly all industries. It notably transforms the pharmaceutical world from drug discovery to production and even sales. Whether it is creating AI brains for companies to build digital workers to help their human employees or streamlining the factory with ultra-reliable predictive maintenance, the machine learning and artificial intelligence revolution is well underway. Curious to Know More? Listen to the conversation between A View On host Martina Hestericová and two world specialists about the present and future applications of AI and Machine Learning in the pharmaceutical industry. KEY TERMS IN CONTEXT: Artificial Intelligence is a field of computer science where simulations of human intelligence by computer processes are used to improve the performance of machines. Machine Learning is a subset within the field of AI that is inspired by the way humans learn. Computational programs in the form of algorithms continually evolve by "learning" or processing information through trial and error, often with the help of human intervention. The goal of machine learning is to create machines that are independent learners capable of solving problems without human involvement. An AI brain, or digital brain, is the term used by OKRA CEO Dr. Lubna Bouarfa to describe a form of AI that learns from several data sets to create a company-specific intelligence to aid decision-making and predictions. For Bouarfa, the company's product can be employed to solve many of the current bottlenecks and problems in Life Sciences and pharma. Synthetic route optimization is used to map out the best way that a scientist can synthesize a compound. With the help of machine learning and AI, this route can be even further optimized by harnessing vast data sets and predicting outcomes. It is only one of many avenues where AI can greatly improve the efficiency of existing technologies in pharma manufacturing. In edge computing the computational work happens outside of the cloud and closer to the actual data event, which allows for real-time processing. With bigger data sets needed to feed in-house AI systems, edge computing architecture holds many advantages for companies looking to harness the power of AI for functions such as automation and safety.

From the International Space Station to Desktop Printers, 3D Bioprinting Is Revolutionizing Tissue Model Research Allevi CEO Ricky Solorzano talks to Lonza about how his company is empowering scientists to print their own tissue models Scientists have been printing cells for decades, but with the arrival of 3D bioprinters, getting printed tissue models to behave like living tissue has proved elusive. That is why angiogenesis and vascularization are two holy grails of 3D bioprinting. A recent article published by researchers at biotech company Allevi demonstrates breakthrough research in which a skin tissue model printed on one of their desktop models showed both processes simultaneously. The April 2020 publication in ACS Biomaterials, Science & Engineering illustrates just how fast bioprinting is moving, producing results that were unimaginable five years ago, facilitating the study of tissue models in basic science, disease modeling, and drug discovery. But Allevi is not stopping at Earth-bound breakthroughs. The US company has also secured funding for simultaneous bioprinting experiments on the International Space Station. Curious to Know More? Listen to the conversation between Lonza and Allevi CEO Ricky Solorzano about both the current state of bioprinting and its future applications in the first episode of the podcast “A View On.” KEY TERMS: Desktop 3D bioprinting: 3D bioprinting, a process similar to other additive manufacturing techniques, uses bioinks and biomaterials to create biomedical parts for research like skin tissue and organoids such as corneas. These printers have traditionally been voluminous, complicated, and costly. Allevi’s desktop 3D bioprinters are not only smaller, they are easy to use and significantly less expensive than larger models. Bio-extrusion: A standard 3D printer at home or in a maker lab makes an object by adding material layer by layer. In bio-extrusion, bioinks are extruded from the nozzles and printed onto a biomaterial matrix. Bioink: A material composed of living cells and biopolymer gels that, once extruded by the printer, can be organized into tissues, organs, and organoids. Matrigel™: The trade name for the substrate used for culturing cells, essential in the bioprinting process as it is often the surface onto which the bioink is printed. Angiogenesis: From ancient Greek, literally the creation (genesis) of vessels (angio). In modern biology, the term refers to the formation of new blood vessels within a tissue. In bioprinting, the presence of angiogenesis means that the printed tissue is behaving and growing in a way that is akin to living tissue and is essential to the success of creating functional printed tissues and organs. Vascularization: Also related to the creation of blood vessels but, in contrast to angiogenesis, successful vascularization of a printed tissue is when an existing, printed structure of blood vessels is adopted by the tissue to delivering blood throughout the structure. Innervation: The process by which a tissue is supplied with nerves. In 3D bioprinting, supplying a printed tissue with nerves is the latest frontier of the technology as supplying tissue not only with blood but also nerves could possibly accelerate restoration of muscle function in vivo and create more complex tissue models for research on neurological diseases.

Antibody-drug Conjugates: Next-Generation of Targeted Cancer Treatments Iwan Bertholjotti and Lawrence Bonnafoux from Lonza give an insider look at how these promising treatments make it from development to commercialization. Chemotherapy is the first-line treatment for most types of cancer. However, one of the major challenges with this approach is that it targets both cancer and healthy cells, with patients suffering severe side effects. A new class of therapies, called antibody-drug conjugates, or ADCs, can target tumors much more precisely by harnessing the power of antibodies. The antibody can bind specific types of tumor cells, delivering a fatal blow to the cancer cells while sparing healthy cells. These promising new drugs have seen a significant uptick in FDA approvals in recent years, pointing towards a trend that could transform the way many diseases are treated. While numerous companies succeed in developing promising ADCs, manufacturing such complex and highly potent treatments presents unique challenges. The intricacy of scaling up the manufacturing of ADCs leads many companies to outsource their production, and Lonza currently fabricates the majority of ADC therapeutics in the world. For the companies that choose to work with Lonza, the collaboration simplifies the process and streamlines the supply chain. Decades of collective experience in fabricating ADCs means that the drugs make it from discovery to approval in less time, improving patients' lives through more effective, targeted treatments with fewer side effects. Curious to Know More? Listen to the conversation between A View On host Martina Hestericová and two of Lonza’s experts on ADC manufacturing—Lonza’s senior director of Commercial Development of bioconjugates, Iwan Betholjotti, and Lawrence Bonnafoux, Lonza’s Head of MSAT BioConjugates. KEY TERMS IN CONTEXT: Bioconjugates are a class of biopharmaceuticals developed by attaching two molecules together, of which at least one is a biomolecule. Examples of bioconjugates include antibody-drug conjugates (ADCs), PEGylated proteins, and vaccine conjugates. Antibody-drug conjugates consist of three parts: an antibody, a cytotoxic drug and the linker that covalently binds these two together. This approach combines the targeted delivery of the antibody with the cancer-killing power of the cytotoxic drug that would be too potent to be used on its own. A cytotoxic drug is a drug that contains a molecule toxic to cells, leading to cellular death. Used in traditional chemotherapy, these molecules attack both healthy and cancerous cells. When linked to an ADC antibody, they target only the tumor. Targeted delivery of a cytotoxin is when a cell-killing toxin is delivered to a specific type of cell, such as tumor cells. This specificity allows for effective cancer treatment with fewer unwanted side effects for the patient. Scaling-up production for bioconjugates involves moving from manufacturing small batches for clinical trials to large batches up to five kilograms for commercial production. This major challenge for companies is essential for the successful commercialization of ADCs.

Our experts reveal the third of three steps to industrialize cell & gene therapy processes: ‘Deliver to GMP’. Transferring the manufacturing process into GMP suite starting with pilot and training runs. To learn more, visit: https://pharma.lonza.com/offerings/cell-and-gene-therapies/process-development

Off-the-shelf Cell Therapy Remestemcel-L Targeting the Lethal Complication of the COVID-19 Pandemic Mesoblast CEO Dr. Silviu Itescu speaks to Lonza about the company’s advanced portfolio of anti-inflammatory allogeneic cellular medicines including remestemcel-L, which is currently being evaluated in a U.S. Phase 3 randomized controlled trial for acute respiratory distress syndrome (ARDS), the principal cause of mortality due to COVID-19 infection. Most COVID-19-related deaths result from ARDS, an overactive immune response that creates overwhelming inflammation in lung tissue. As the world suffers in the grip of this pandemic, some hope comes from Mesoblast. They have dedicated the past 15 years to developing a portfolio of product candidates based on mesenchymal lineage cells to treat severe inflammatory diseases such as graft versus host disease, advanced heart failure, and chronic low back pain. Their strategy for treating inflammatory diseases uses cellular medicines instead of small molecules or monoclonal antibodies, thereby treating an out-of-control immune system on a systemic level by impacting multiple inflammatory pathways at the same time. This positions them well to provide much-needed treatment for those COVID-19 ARDS patients left with few – or no – options. The Phase 3 trial was informed by the positive results from an emergency compassionate use protocol in patients on mechanical ventilation with COVID-19 ARDS at Mt Sinai Hospital in New York where 75% (nine of 12) patients were discharged home compared to a mortality rate of around 80% recorded in New York over the same time period in patients with COVID-19 ARDS who were not treated with remestemcel-L. Interim analyses of the 300-patient trial are planned, and Mesoblast Chief Executive Dr. Silviu Itescu is eagerly awaiting results. Curious to Know More? Listen to the conversation between Lonza and Mesoblast Chief Executive Dr. Silviu Itescu in this episode of the podcast, "A View On." KEY TERMS: Cellular medicine: The use of cells already found in the human body, frequently modified and enhanced, to treat diseases. Mesenchymal lineage cells: Cells whose function is to sense tissue inflammation through specific receptors for inflammatory cytokines and then secrete anti-inflammatory factors. They are present in all vascularized tissue and act as regulators that enable normal immune response in all organs. To learn more, visit: www.mesoblast.com/science/mesenchymal-lineage-cells. Immune cascade: When the body’s complementary immune system produces additional proteins, such as cytokines, to enhance the ability of antibodies to defend against microbes and damaged cells. Cytokines: These extremely small proteins, important in cell signaling, modulate immune responses. Mesoblast’s mesenchymal lineage cells interact with cytokines to modulate the inflammatory response of the immune system. Cytokine storm: This is when the body quickly releases too many cytokines into the blood, creating an exaggerated immune system inflammatory response that can be harmful and even deadly. Multimodal immune activation: When the body activates multiple immune responses to attack a virus or foreign body, potentially leading to dangerous inflammation of tissues in vital organs. The advantage of Mesoblast’s technology is that, unlike small molecules and monoclonal antibodies, their cellular medicines can simultaneously regulate several of these responses.

mRNA is one of the most exciting fields in medical science today. Lonza’s partnership with a customer in that area to manufacture COVID-19 drug substance has proven our operational capabilities in mRNA. Setting up new production lines in our Portsmouth, NH (US) and Visp (Switzerland) facility has taken a matter of months rather than years thanks to Lonza’s pre-investment in state-of-the-art facilities and the dedication of our teams. This work has disrupted how medicines are created, permanently. There are many possibilities to target infectious diseases and life-threatening viruses using mRNA technology. Our expertise has the potential to shape the future of immunity medications. With so much growth opportunity in mRNA, we offer the chance to make a real impact on the manufacturing technology behind game-changing treatments. Join us and make a Meaningful Difference: https://www.lonza.com/careers/job-search?utm_medium=referral&utm_source=youtube&utm_campaign=evpl-videos&utm_content=mRNA

Cell and gene therapies are becoming the new frontier in medicine; they are generating hope for many patients where there are no other options to provide meaningful benefits. At Lonza in Cell & Gene Technologies (CGT) we are proud to be enabling and accelerating their global delivery through our sites in the US, Europe and Asia. With products and services for allogeneic and autologous cell therapies, as well as viral vector gene therapies, we are working on novel therapies using cutting-edge technology to push boundaries in healthcare. As we break new ground within our industry, we are attracting customers worldwide. They include companies large and small. However it’s not just the scale of our ambitions that draws them, it’s our heritage and credibility. With a history that dates back to 1897, Lonza is a trusted name that’s acquired a wealth of knowledge and expertise in the field of Life Science. Join us and contribute to the life-changing therapies of tomorrow.

In Portsmouth, NH our team of 1,200 employees enables our customers to deliver new and innovative medicines by pioneering mammalian and cell therapy custom development and manufacturing services. At nearly 700,000 ft2, our site manufactures products from more than 50 cell lines. Our state-of-the-art GS-system for expression of monoclonal antibody proteins is licensed by some 257 products in active human trials and 56 marketed products. But there are more advantages here than the work alone. The location also offers the benefits of beautiful New Hampshire, being close to the ocean and mountains and just 56 miles away from Boston. Join our team and make a Meaningful Difference with us: https://www.lonza.com/careers/job-search?q=*&pg=1&rows=30&job_location_facet_sm=United+States%2c+Portsmouth+(New+Hampshire)#search-results

Bridging Business and Biotechnology: Kodiak Sciences Is Increasing Treatment Efficacy for Retinal Diseases Victor Perlroth, MD, the Chairman and CEO of Kodiak Sciences, discusses how the company’s ABC platform medicines are designed to treat the leading causes of blindness. Age-related macular degeneration (AMD) is one of the leading causes of blindness in adults worldwide. This disease deteriorates the macula, a miraculous little spot on your retina that allows for precise vision in good light. Although several treatments exist for macular deterioration, they require frequent trips to the doctor’s office for uncomfortable but quick and routine injections directly into the eye. The required frequency of the treatments means that most patients miss appointments, leading to undertreatment of the disease and permanent vision loss. In a manufacturing collaboration with Lonza, Kodiak is designing novel antibody-biopolymer conjugate (or ABC) medicines with the same efficacy and safety with much longer durability, allowing patients to visit the doctor on a realistic schedule over the long term. By focusing on business implementation alongside formidable biotech R&D, Kodiak Sciences is on track to bring together the necessary clinical and manufacturing elements for an FDA filing in 2023. Curious to Know More? In this most recent episode of “A View On,” Lonza’s Martina Hestericová is joined by Victor Perlroth, MD, the Chairman and CEO of Kodiak Sciences, to talk about the recent developments in AMD treatment research. KEY TERMS: Age-related macular degeneration (AMD) is a common degenerative disease of the retina. There are two types of AMD: Dry AMD occurs when the formation of debris (drusen) on the retina causes the macula to deteriorate over time. Patients sometimes experience vision loss and frequently experience substantial functional limitations, including vision fluctuations, loss of peripheral vision, and reduced night vision. Wet AMD is an advanced form of AMD. While wet AMD represents only 10% of the number of cases of AMD overall, it is responsible for 90% of AMD-related cases of severe vision loss. Wet AMD occurs when the growth of abnormal blood vessels underneath the macula leads to leakage of fluid and blood, which leads to visual distortion, acute vision loss, and total blindness if left untreated. Vascular endothelial growth factor (VEGF) is a sub-family of factors that stimulate the growth of blood vessels. In the case of AMD, these VEGF are overexpressed, creating leaking in the macula. This leakiness causes fluid to exit from blood vessels, causing swelling – or edema – of the retina and loss of vision. An antibody biopolymer conjugate (ABC) is Kodiak Science’s proprietary platform for designing and developing drugs into the retina. The antibody in the KSI-301 molecule inhibits VEGF, while the biopolymer is comprised of phosphorylcholine, which creates a sort of “water cloak” around the antibody to increase its effectiveness. Phosphorylcholine is a natural component of the cell membrane of all the cells in our body, with remarkable properties. It attracts and binds water in a very strong – even permanent – way, creating what is known as “structured water,” which then impacts all biological interactions in the local area.

Host and Health: Tailoring Personalized Medicine Using The Unique Microbiome Fingerprint Professor Eran Elinav from the Weizmann Institute of Science discusses how the interaction between the microbiome and its host is transforming personalized medicine. “I believe that in the next five to ten years, exploiting the potential of the microbiome will be central to personalized and precision medicine,” explains Eran Elinav. His research into this second genome in the human body at the Weizmann Institute of Science in Isreal is shedding light on how these trillions of cells function and interact with their host. The individualized data from the unique microbiome fingerprint can be harnessed to tailor nutritional therapies to improve metabolic functions in the treatment of, for example, obesity and type 2 diabetes—with a wide range of further potential applications. And even small molecules found within the microbiome could themselves be developed into drugs. The future hope lies in the inherent therapeutic translatability of these insights from host-microbiome interaction research into treating the whole spectrum of metabolic diseases. Curious to Know More? Listen to the conversation between Lonza’s Martina Hestericová and Weizmann Institute of Science Professor and researcher Eran Elinav in this special episode of the "A View On" podcast. KEY TERMS IN CONTEXT: Genome: All of the genetic information of an organism. When speaking about the microbiome, it refers to an entirely different organism that is comprised of its own genetic makeup from the host—the interaction between the two genomes is the subject of study known as host-microbiome interaction. Microbiome: The extremely diverse ecosystem of hundreds, sometimes thousands of different species of microbes found in and on the human body. Microbial biodiversity is key to a healthy microbiome and a poor microbiome is linked to diseases such as inflammatory bowel disease, cancer and possibly some central nervous disorders. Therapeutic translatability: The ability to translate or apply basic research into therapies for the benefit of humans. As we understand more how the complex microbiome works, Professor Elinav asserts that these insights translate directly into ways to manipulate it and improve health. Personalised or Precision Medicine: A general trend to adapt treatments to individuals instead of a one-size-fits-all approach. In the context of host-microbiome research, as the microbiome is unique to each individual, it could hold the keys to specialized treatments by harnessing the individualized data.

In late 2022, China introduced the world’s first Covid-19 vaccine to be inhaled into the lungs. But vaccines are just the tip of the inhaler iceberg. A whole range of therapeutic options for many diseases are becoming available through the technology known as dry-powder inhalers, or DPI. Still, getting the correct amount of the molecule to the right part of the lung is tricky business. New manufacturing techniques and new types of molecules make drug inhalers a continually evolving field full of potential advantages for patients. Listen to this episode of A View On Manufacturing Inhaled Drug Products to learn more about what it takes to develop effective treatments with insights from Lonza’s Associate Director, R&D, Kim Shepard and Matt Ferguson, Lonza’s Head of respiratory drug delivery.

Capsule Manufacturing: It’s Not Only What’s Inside That Counts The recent EU ban on Titanium Dioxide and changing customer habits are shaking up capsule production. Over the past few years, the coloring and manufacturing of pill capsules have undergone significant changes due to new EU regulations and customer demand for natural ingredients. And while originally invented to mask and protect the contents inside a capsule, research suggests that the color of a tablet or pill can affect how patients feel about their medication. Until recently, manufacturers have primarily used Titanium Dioxide (TiO2) to create white capsules due to its efficiency in protecting the active ingredients from UV rays. However, this year an EU-wide ban on TiO2 has forced the industry to move towards alternatives that work as well, or better, than TiO2. To add to the colorant shake-up, many people are actively avoiding unnatural ingredients in their food and nutritional supplements, which has created a new demand for plant-based capsule colorants. Anticipating these changes and solving the technological challenges in a timely manner are key to a successful long-term strategy for capsule manufacturing. Curious to Know More? Listen to the conversation between A View On host Martina Hestericová and Ljiljana Palangetic, Lonza’s Associate Director of Hard Capsules R&D, about the challenges and solutions in current capsule manufacturing. KEY TERMS IN CONTEXT: Pharmaceutical capsules can be either hard or soft. Soft-shelled capsules are one unique mold that encapsulates the contents, whereas the more widely-used hard-shelled capsules—such as the ones produced by Lonza—are two molded telescopic pieces of capsule: a smaller one contains the active ingredients, and a larger one encloses the capsule. Titanium dioxide (TiO2) is a widely-used pigment in capsule manufacturing, as well as in food, paint and sunscreen. Considered completely inorganic and nontoxic from a chemical point of view, it is labeled as an unnatural ingredient for ingestion, and carries the E number E171. Earlier this year, the European Food Safety Authority (EFSA) announced a six-month phasing-out ban of the colorant over concerns about nano-sized particles of TiO2 accumulating in the body. The full ban takes effect in August. The dip molding process is the manufacturing process for capsules. The final shape of the two pieces that make the capsules is defined by specifically designed molds, which are dipped in a bath of liquid formulation to pick up material that will, after the drying process, give the final capsule form, shape and composition.

Erik Lemay, Head of Global External manufacturing at Servier discusses L-asparaginase production with Lonza, the active pharmaceutical ingredient for Servier’s Acute Lymphoblastic Leukemia (ALL) therapies, and how the collaboration with Lonza has delivered a manufacturing process that gives a 20% improvement in product yield. "Lonza has produced L-asparaginase for over 10 years, they have the technical expertise and the process knowledge, to be able to produce our medicine at a high quality" - Erik Lemay Learn more about Lonza and our microbial fermentation services: https://www.lonza.com/biologics/microbial

Devouring Bacteria: How Phage Therapy Is Shaping Antibacterial Treatments of the Future In this episode we speak with the CEO of BiomX, Jonathan Solomon, about producing and using phages to test and treat various diseases and conditions. Until very recently, treating a condition such as acne with an army of microscopic bacteria-destroyers known as phages—bacterial viruses that target and kill specific bacteria—would have seemed highly unlikely. However new research linking acne to an imbalance in the skin’s microbiome has opened the door to innovative treatment approaches. That’s where the biotech company BiomX comes in. Uniting powerful computational science with the inherent capacity of phages to destroy specific bacteria, BiomX creates natural and synthetic phage therapies for some of the most troublesome bacteria-related health issues: acne, atopic dermatitis, cystic fibrosis, inflammatory bowel disease (IBD) and even colorectal cancer. For acne the company has developed a successful cocktail of three different phages to treat the condition, with phase 2 testing close on the horizon. BiomX’s developments in phage therapy promise to change the way we treat imbalances in our microbiome, with potential health benefits for large swaths of the population. Curious to Know More? To learn more about BiomX, listen to the conversation with Jonathan Solomon on this episode of A View On: Phage Therapy. KEY TERMS: Bacteriophage (also known as a phage): A virus that attacks and devours only bacteria (‘phagein’ in Ancient Greek means to devour). Bacteriophages are bacteria-specific, which is both an advantage and disadvantage in manufacturing treatments. Fun fact: taken altogether, bacteriophages are the most numerous entity on the planet. Phage cocktail: Since a phage targets and destroys only one type of bacteria, treatments for complex ailments necessitate a mixture, or cocktail, of different phages to be effective. Phage fermentation: Although destructive, unwanted phages can grow during fer-mentation processes for wine-making and milk production, fermentation is neverthe-less the optimal way to produce phages for therapeutic uses. Computational (science): Computer modelling of the phage and its potential inter-action with specific bacteria (known as in silico testing) allows researchers to develop phage cocktails more efficiently and with a greater chance of success.

From small beginnings in the Swiss Alps more than 120 years ago, we have grown and developed to become a leading partner to the healthcare industry. Today, we are a unified company with a global network of more than 30 sites and 15,000 employees. Our Lonza family is united by a common purpose - to enable #AHealthierWorld. This purpose is our reason for being and what motivates us to succeed, every single day. Together, we make #AMeaningfulDifference.

Matt Ferguson is a Senior Principal Investigator within Product Development for Inhalation Programs at Lonza’s site in Bend, Oregon. His work is focused on developing innovative i#nhalation technologies including dry-powder inhaler (DPI) formulations. Learn more about our “Meet the Experts” video series here: https://pharma.lonza.com/knowledge-center/meet-the-experts

Developing Cell Culture Media For Growing Cells We are back! And in the first episode of our new season, we explore growing cells for therapeutic purposes with Lonza specialists Alexis Bossie, Director of Media R&D, and Tariq Haq, Senior Director of Global Media Marketing. Lab-grown meat is having a moment—the FDA just declared one company’s cultivated chicken safe to eat, and another type of lab poultry was just served for dinner to delegates at this year’s COP27 climate conference in Egypt. Whether this piques your pallet’s curiosity or turns your stomach, one thing is clear: growing meat in a lab for human consumption will take massive amounts of cell media. What is cell culture media? It is the medium in which cells grow in a lab, serving as both the cell’s food and its shelter. The medium can take various forms, depending on which cell type is being grown and for what specific purpose. It is a careful recipe that balances the complex needs of cells in nutrients, energy, pH balance and saline per-centage. Like our bodies, cell culture media is mostly water. However, crafting the right media is no simple matter: choosing the correct formula can make all the difference for the cell growth outcome, whether trying to stimulate virus production or make the tastiest animal-free cultivated cordon bleu on the planet. Curious to Know More? Listen to this episode of A View On to learn more about what it takes to grow cells in a lab. As a bonus for our listeners, at the end of the discussion, Alexis Bossie shares insights into the possibilities and obstacles of growing meat in the lab. KEY TERMS IN CONTEXT: Cell culture media is the medium in which cells grow. It must meet all environmental conditions to keep a cell alive and flourishing. Either as a liquid or gel, synthetic or organic, the cell culture media’s most important function is to deliver nutrients to cells and to wash away waste products. The osmotic balance in cell media is the salt and water balance needed to maintain proper cell functioning. An imbalance creates uneven flows of water between a cell and its media, resulting in a cell burst or cell shrinkage. A protein factory is a name given to batches of cells cultivated in a laboratory to produce high quantities of one or several types of proteins, often for therapeutic purposes. It must not be confused with the cell’s own protein factory, aka the ribosome. The metabolomics and proteomics are the biological disciplines describing the metabolites and proteins in a cell. As these fields advance, so does the understanding of cultivating cells and developing the correct media for each type of desired growth and outcome.

Cannabinoids are emerging as a treatment option for autoimmune and other immune-related diseases thanks to their modifications as synthetic derivatives. Emerald Health Pharmaceuticals has widened the potential application of cannabinoids by designing cannabidiol and cannabigerol derivatives that have a greater effect on the endocannabinoid system and can interact with receptors and pathways from other biosystems. Alain Rolland, COO of EHP, talks about using cannabinoids for unmet medical needs.

Surrozen is a small biotech developing novel and complex bispecific antibodies that target activation of the WNT pathway to take advantage of its regenerative potential. Although the WNT pathway has been studied for decades, Surrozen is aiming to develop the first therapeutics that intervene in this pathway, and only in diseased tissue. While still working on antibody engineering work, Surrozen was keen to get started quickly on process development and manufacturing, and knew that it needed a CDMO with experience developing and producing bispecific antibodies and fusion proteins. This led to engagement with Lonza, who showed great appetite for the novel science and embarked on two programs at the same time. Lonza’s scientists worked seamlessly with the California-based biotech to advance the challenging molecules to the point of being in the clinic in 2022. Learn more about Surrozen’s experience with Lonza from its President & CEO, Craig Parker: https://www.lonza.com/knowledge-center/biologics/a/small-biotech-success-surrozen

During drug development, it is critical to balance risk with time and costs. We understand the complexity of building such optimal paths. By offering flexibility on your journey to IND, we can shape our process around your molecule’s profile, critical milestones and company’s needs. Our flexibility extends to commercial terms, enhanced portability and specific program guarantees. Giving you even more reasons to choose Lonza. The people powering biologics.

While at a Big Pharma, Simon Westbrook had an idea for a complex fusion chimera protein he believed could interrupt the neurotrophin pathway and have a profound impact on chronic pain and joint degeneration in osteoarthritis patients. He formed Levicept to develop this idea and being a true virtual company, he needed a CDMO. By his own admission, he was looking to work with the best. After a consultant recommended working with Lonza early on, Simon bonded with Lonza’s scientists in Cambridge, UK as they worked together on coupling the extracellular domain to an IGGFC. With this being such a complex protein, flexibility was required in the process and a lot was learned along the way. The molecule demonstrated the differentiating efficacy Simon was looking for, and is now in Phase II. Learn more about Levicept’s journey with Lonza from Founder & CEO, Simon Westbrook: https://www.lonza.com/knowledge-center/biologics/a/small-biotech-success-levicept

Want to become part of our team in Quality Assurance (QA)? At Lonza we work at the forefront of science, technology and manufacturing to enable #AHealthierWorld. In QA, we define policies and set the operating procedures in cutting-edge facilities to support that vision. That means when you join us, you are in an environment that is fast-paced, dynamic and challenging - all of this to bring treatments and therapies to the patients who need them the most. Want to learn more? Watch this video, then search opportunities to help us in making #AMeaningfulDifference.

We’re impacting lives. The lives of patients, healthcare consumers – and the lives of the people who work for us. Meet some of our employees from Lonza Greenwood, to find out how.

From solving problems to touching people’s lives - three of Lonza’s employees tell us what they love most about working on Lonza's exciting construction projects. Providing insights into the unique spirit of the engineering team. #JustImagine

Exosomes Know Where To Go: Using the Body's Own Cell-to-Cell Communication Network for Diagnostics and Drug Delivery We speak with Uwe Gottschalk, the Chief Scientific Officer of Lonza, about how a better understanding of exosomes is leading to new treatments and diagnostic technologies. According to Uwe Gottschalk, the exosome revolution is already in full march. As researchers begin to identify how these cell-generated, nano-sized delivery drones function in the human body, novel drug delivery prospects are emerging, including applications for cancer, neurodegenerative diseases and spinal cord injury recovery. Perhaps even more exciting is the role exosomes will play in diagnostic applications in the near future, wherein a liquid biopsy, based on a blood sample, would detect cancer or other diseases both more easily and in a more timely fashion than traditional biopsies. One of the many challenges is the ongoing task of defining the manufacturing protocols and processes for this new biotechnological paradigm. Even so, the field is abuzz with new discoveries, trials and general optimism about the potential of these microscopic extracellular delivery vehicles. Curious to Know More? Lonza's Chief Scientific Officer gives us his expert insight into exosome research and application in this special, in-house episode of the podcast "A View On."

A short video highlight of what makes our dedicated cell & gene therapies site in Houston so special.

At our site in Houston, TX you will experience the best of both worlds: more from your career, and more from life. Our site was the world’s largest dedicated cell and gene therapy facility at its opening and is approved for commercial manufacture by the FDA. We offer innovative end-to-end development and manufacturing services across a variety of modalities and technologies as well as are the centre-of-excellence for process development activities. But Houston can offer you much more: Visit the world famous Rodeo show and Space Center, enjoy with friends and family countless beautiful waterways and parks, relax at the beach and many more. Join us and make a Meaningful Difference with us: https://www.lonza.com/careers/job-search?q=*&rows=100&job_location_facet_sm=United+States%2c+Houston+(Texas)

New Arsenal in the Battle Against Cancer: Pharmaceutical Smart Bombs Promise Less Collateral Damage for Patients Cybrexa Therapeutics CEO Per Hellsund and CSO Vishwas Paralkar talk to Lonza about how their enterprise is shaping the future of cancer treatment with cell-penetrating peptides. One of the biggest obstacles to safely eliminating cancerous cells is that most therapies also negatively impact a patient's healthy organs and tissues, known as bystanders. This notorious problem has hindered effective treatment since the beginning of oncology and often has devastating effects on patients’ quality of life. One novel strategy pursued by Cybrexa Therapeutics is the design of treatments that specifically target solid tumors made of cancer cells by taking advantage of one of their universal biomarkers – acidity. The company has developed a platform that leverages the low pH environment inherent to cancer cell metabolism. By using cell-penetrating peptides bearing an anticancer cargo load, their platform brings the treatment directly inside tumors, leaving healthy cells alone and minimizing bystander killings. This smart anti-tumor technology promises to be applicable to a wide swath of patients and reduce side effects of cancer treatment Curious to Know More? Listen to the conversation between Lonza and Cybrexa Therapeutics researchers in this episode of the podcast "A View On." KEY TERMS: Acidity of cancer cells: Current research shows that cancer cells exhibit a type of cell metabolism known as aerobic glycolysis, a process that generates lactic acid and creates a more acidic environment in and around tumors. Cell-penetrating peptide: Peptides are strings of amino acids that can be utilized for drug delivery. They are wobbly in structure and ineffective at penetrating cells under normal pH levels but rigidify when reaching acidic environments and can then enter the targeted cell. Linkers: A chemical bond that allows for a drug to attach to its carrier and be delivered to a specific target. For Cybrexa, this bond connects the peptide to the cytotoxic molecule or DNA inhibitor for the efficient targeting of cancer cells and tumors. Cytotoxic drugs: Cytotoxic drugs in cancer therapy, such as chemotherapy, are not only toxic to cancer cells but do damage to other healthy cells, creating unwanted side effects to treatment. New research is showing how, when combined with cell-penetrating peptides, cytotoxic molecule delivery can be limited to the acidic environments of cancer cells, thereby avoiding off-target toxicity and bystander killings. DNA repair inhibitors: A relatively recent form of cancer treatment that oncologists often use in conjunction with chemotherapy. Inhibiting the repair mechanisms of cancer cells effectively turns the table on the tumor, the cancerous cells of which have hijacked the healthy DNA of a patient and use the cells natural repairing properties to become resistant to chemotherapy. By employing DNA repair inhibitors targeted specifically to cancer cells, researchers hope to increase the effectiveness of chemotherapy and reduce its side effects. Dose-limiting toxicity: When the side effects of a drug or other cancer treatment prohibit a dose increase that would otherwise be beneficial to the cancer therapy. By removing this boundary, therapies could be much more efficient in destroying cancerous cells in the body.

De-risking Drug Development: Early Testing for Toxicity Saves Time and Resources Yvette Stallwood, head of Lonza’s Early Development Services, talks about patient safety and other advantages of early testing for immunogenicity in the drug development pipeline. In the high-stakes drug discovery game, from IND filings all the way up through the clinical trial phase, regulatory authorities are now expecting developers to have an immunogenicity risk strategy in place. “It really is essential that drug developers assess the immunogenicity risk as early as possible in the pipeline, as not only can it impact the functionality of the drug, but it can also be a significant safety risk for the patient,” explains Yvette Stallwood, whose work at Lonza’s Early Development Services (EDS) is helping small and large biotech companies reduce risk with a “Right First Time” approach when developing drug therapies. Drug candidates often fail during clinical trials due to their toxicity to patients, which is evident, for example, in an immunogenic reaction—where the drug triggers an unwanted immune response known as immunotoxicity. This can result in the loss of years of work and funding. Stallwood and her team encourage their clients to begin with in-silico testing, where up to a thousand digital models of potential immunoresponses can be predicted. Once the digital models show a candidate to have a low risk of toxicity, the EDS team then moves to human donor cell assays—with the advantage of screening up to fifty different immunotypes. The ideal time to assess immunosafety and immunotoxicity is well before deciding on a molecule as a lead drug candidate. By understanding as much as possible about the potential product through early testing, biotech companies are better equipped to take the correct path to regulatory approval with a drug that is ultimately safer for patients. Curious to Know More? Listen to the conversation between A View On host Martina Hestericová and Lonza’s head of EDS Yvette Stallwood as they discuss de-risking the drug development process. KEY TERMS IN CONTEXT: Anti-drug antibody (ADA) response happens when the patient’s immune system generates antibodies to remove and clear the drug from the body. This can impact the effectiveness of the drug molecule as well as be dangerous for the patient. Immunogenicity testing is the process by which one can test for the body’s immune response to a drug. With in-silico testing, the screening can be done quickly for a large swath of different immune system typologies before moving on to animal models or, preferably, human cell assays. Immunosafety and immunotoxicity refer to how potentially safe or toxic the immune system’s reaction to a molecule may be. They deserve the utmost consideration when developing a leading drug candidate. De-risking is an EDS drug development strategy to ensure clients select the right drug candidate at the approval phase. De-risking avoids costly clinical trial failure through extensive immunotoxicity testing early in the process. In-silico testing uses computer models to test a molecule’s reaction within an organism, such as a human immune system. The advantage is that they are quick and can test in hundreds and thousands of models. Since they are limited in their nature, they are only a first step. Once a drug candidate is selected as low risk using in-silico testing, further testing is needed using animal models or human cells assays. Human cell assays, in the context of drug development de-risking, are in-vitro tests that use actual human immune cells to test immune system responses to drug candidates. Although they are more costly and time-consuming than in-silico testing, the precision they offer is essential to establish the appropriate data for selecting lead drug candidates.

Geleen in the Netherlands is home to our European Center of Excellence for process development and manufacturing and is part of Lonza’s global network of cell and gene therapy expertise. As the custom development and manufacturing organization that has supported a number of commercial autologous cell therapy products in Europe, we are committed to using our expertise to help customers develop and commercialize treatments quickly and efficiently. As we grow, we are expanding our strategic partnerships and have recently announced to manufacture mRNA vaccine drug substance. But the location can offer more. Being located in the southern Netherlands you can enjoy flexibility on where to live and the local lifestyle. Join us and make a Meaningful Difference with us: https://www.lonza.com/careers/job-search?q=*&pg=1&rows=100&job_location_facet_sm=Netherlands%2c+Geleen&job_location_facet_sm=Netherlands%2c+Maastricht

In Product Development, our scientists are exploring the unknown to create the next generation of treatments. We currently have 100 compounds, including 30 cancer compounds, in development. Join our team in Product Development: https://www.lonza.com/careers/job-search?q=*&pg=1&rows=100&job_location_facet_sm=United+States%2c+Bend+(Oregon)&job_posting_family_s=Research+%26+Development&utm_medium=referral&utm_source=youtube&utm_campaign=evpl-videos&utm_content=ProductDevelopmentSM

At Lonza, we have a broad range of backgrounds, cultures and perspectives, with more than 100 nationalities represented across over 30 countries, and we all have one thing in common - we live up to our values: #Innovation #Integrity #Inclusion #Initiative The video outlines how we bring our values to life and how these individual behaviors support all of us in fulfilling our purpose of enabling a healthier world. Join us today to make a Meaningful Difference with us: https://www.lonza.com/careers/job-search

It’s the season finale for A View On, the Lonza podcast. Over the past 12 months of our initial run, we have brought you a series of conversations exploring the new pharma and biotechnology trends. We spoke to experts from Lonza and the industry and discussed exciting topics, such as exosomes, stem cells, drug product testing, bioprinting, and much more. In the latest episode, the podcast host, Lonza’s Martina Ribar Hestericová, recaps the highlights from this season and looks forward to later this year for what is coming up in the next season. Interested to learn more? Visit our dedicated podcast site on www.lonza.com/a-view-on and don't forget to subscribe.

Careers insight: meet the Lonza team in Slough producing groundbreaking mammalian biopharmaceutical products to improve treatments for diseases like leukemia. Filmed inside our cutting-edge manufacturing facility, this video features some of our scientists, technologists and program managers talking about the jobs they do ─ and why their work matters. See if there’s an opportunity for you at Lonza on our careers website. https://lonza.wd3.myworkdayjobs.com/Lonza_Careers Want to know more about our manufacturing of monoclonal antibodies and recombinant proteins? https://www.lonza.com/custom-manufacturing/biological-manufacturing/mammalian-biopharmaceuticals.aspx Subscribe to the Lonza channel now https://www.youtube.com/subscription_center?add_user=LonzaGroup

Discover what makes Lonza Slough different to other employers in UK bioscience and mammalian manufacturing. We asked some of our scientists, technicians and program managers for their inside view on working in this unique setting. See if there’s an opportunity for you at Lonza on our careers website. https://lonza.wd3.myworkdayjobs.com/Lonza_Careers Want to know more about our manufacturing of monoclonal antibodies and recombinant proteins? https://www.lonza.com/custom-manufacturing/biological-manufacturing/mammalian-biopharmaceuticals.aspx Subscribe to the Lonza channel now: https://www.youtube.com/subscription_center?add_user=reelseo

CAR-T cell therapy has generated immense enthusiasm within the oncology community since the first FDA approval in 2017. Currently, there are six commercially approved CAR-T cell-based therapies, with more on the horizon. Industry experts Tamara Laskowski and Aya Jakobovits attest to the astounding outcomes witnessed in patients, some of whom have remained in remission for a decade after having received a CAR-T infusion. Join us on this podcast episode as we explore the therapeutic potential of CAR-T cells, their path to clinical trials, and their role in providing astonishing outcomes for patients with limited treatment options.

A short, comprehensive video animation explaining cell & gene therapy and Lonza’s role in this emerging field. We develop and manufacture the key components of cell and gene therapy for our customers and their patients. To learn more visit: http://pharma.lonza.com/cell-and-gene-therapy

Our experts reveal the first of three steps to industrialize cell & gene therapy processes: ‘Diagnose to de-risk’. We establish the baseline process and identify the major manufacturability gaps of the process and come up with the scope of development activities. To learn more, visit: https://pharma.lonza.com/offerings/cell-and-gene-therapies/process-development

Lonza experts Selene Araya and Charles Johnson discuss the manufacturing process, trends, and future of highly potent compounds (HPAPIs). They highlight Lonza's facilities and exper-tise in producing HPAPIs across various technologies and scales, ensuring advanced contain-ment and addressing bioavailability challenges. Join us on this podcast episode as we explore the power and potential of highly potent com-pounds, delve into the challenges faced in their manufacturing, and envision a future where these compounds shape the landscape of sustainable pharmaceuticals.

Join us in celebrating the finale of our second season of A View On, the Lonza podcast. Over the past few months, we have brought you a series of insider conversations with our experts at Lonza, our partners, and leaders in the industry exploring the new pharma and biotechnology trends. We explored exciting topics, such as oncolytic viruses, the human microbiome, antibody-drug conjugates, nuances of early drug development, capsule manufacturing, and the use of artificial intelligence in the pharma industry. In the latest episode, the podcast host, Lonza’s Martina Ribar Hestericová, recaps the highlights from this season and looks forward to later this year for what is coming up in the next season. Interested to learn more? Visit our dedicated podcast site on www.lonza.com/a-view-on and don't forget to subscribe.

Season three so far, we’ve covered a lot! In this summary episode, A View On host Martina Hestericova shares a secret and goes over a selection of the best ideas from season three so far. The production team for A View On has managed to keep things moving along smoothly, so you most likely didn’t even notice that Martina was away for four months. She’s back! Listen in as Martina navigates us through a curated selection of the finest moments from the season: from cell culture to highly potent molecules, from inhalants to gene therapies, we’ve covered a lot this season. Check out this summary episode and stay tuned for future topics such as antibody based therapies, health ingredients, and even forensic science.

Hear from our veterans and where they are now in Lonza Greenwood

In Drug Product Services, we are more than 600 dynamic, talented people, drawn from all corners of the world. We focus on the final stage of the lifecycle, we develop formulations and processes, as well as manufacturing and testing non-clinical, clinical and commercial supplies for our customers’ drug treatments. Join a culture that is more like start-up than a global business. Join our team and make a Meaningful Difference with us: https://www.lonza.com/careers/job-search/careers-in-dps

Alicia Levey and Kiren Khanduja of Pionyr Immunotherapeutics –– a San Francisco-based biotech with a pipeline of first-in-class clinical-stage cancer immunotherapies targeting the tumor microenvironment –– discuss the basis for selection of Lonza to meet Pionyr’s goals to rapidly develop a third lead candidate from the start and to scale-up manufacturing of two clinical-stage immuno-oncology treatments after tech transfer. Learn more about Pionyr's story: https://www.lonza.com/knowledge-center/biologics/a/small-biotech-success-pionyr

Corvus is a small biotech developing precision medicines, primarily for oncology patients. It came to Lonza seeking to develop a monoclonal antibody called CPI06, now known as Mupadolimab. This inhibits the production of adenosine in the tumor microenvironment and has an agonistic effect on B cells. When considering CDMOs for CPI06, Corvus was aware of Lonza’s platform methodology, custom built for mAbs, and its track record commercializing antibodies. Lonza welcomed Corvus and demonstrated flexibility taking on the project by starting work with available capacity in Singapore and then transferring to Slough, UK. Multiple consistent batches were manufactured, and the product is currently in clinical trials with CMC work simultaneously taking place to provide a good regulatory platform with a goal for commercialization. Learn more about Corvus’ experience with Lonza from its SVP of Pharmaceutical Development, William B. Jones: https://www.lonza.com/knowledge-center/biologics/a/small-biotech-success-corvus

Watch the groundbreaking and time capsule ceremony for our new large-scale commercial drug product manufacturing facility in Stein, Switzerland. The event, which took place on January 31st, 2023, marked the official beginning of construction for the new facility. Once finished, the new facility will allow us to provide our customers with an end-to-end offering across the entire drug product lifecycle. Representatives and local authorities from Canton Aargau joined us to celebrate the occasion.

On January 31st, we held a ribbon cutting event to celebrate the inauguration of our newly expanded Process and Analytical Development laboratories in Houston, Texas. We were joined by more than 120 participants, including attendees from pharmaceutical and biotech companies, global and local partners as well as local government officials.

Launch with Lonza™ innovation services offers a full suite of concept-to-market services to turn ideas into breakthrough products. At Lonza, we’re driven by our purpose to enable a healthier world. It’s the ‘why’ behind everything we do and it’s the driving force behind our Launch with Lonza™ innovation services. Whether you’re looking for that next big idea or need formulation and manufacturing support, our end-to-end services help you get to market—fast.

Durch unsere Mitarbeitenden sind bei Lonza mehr als 100 Nationalitäten vertreten, eine Breite an Kulturen und Perspektiven, die in über 30 Ländern verteilt ihrer Aufgabe nachgehen, und doch haben wir alle eines gemeinsam - unsere Firmenwerte: #Innovation #Integrität #Inklusion #Initiative Im Video lernst du wie wir unsere Werte leben und wie uns diese unterstützen, eine gesündere Welt zu ermöglichen. Möchtest du ebenfalls Teil der Lonza-Familie werden? Dann bewerbe dich noch heute: https://www.lonza.com/careers/job-search

We are here to make a Meaningful Difference. It is the foundation of the way we do business. A career at Lonza is more than a job. We do not just work in the life sciences industries, we are transforming them. What we do today is helping to create a healthier, happier world tomorrow. Apply today: https://www.lonza.com/careers/job-search

Want to make #AMeanigfulDifference to the health of thousands of people? In Product Development, we are exploring the unknown to create the next generation of Small Molecule treatments. We currently have 100 compounds, including 30 cancer compounds, in development. Sound interesting? Watch this video to discover more, then search opportunities to help us enable #AHealthierWorld: https://www.lonza.com/careers/job-search #ProductDevelopment

At Lonza, we are where technological insight and scientific expertise meet world-class manufacturing and process excellence. In Engineering, we make our mark by working across Facility, Utility, Project, Instrument, Maintenance and Controls across five continents and more than 35 sites. Everyone gets exposure to new business areas and the latest industry trends to expand their skills and impact. Learn more about Engineering careers in this video, then visit our careers site and explore the opportunity to make #AMeaningfulDifference. https://bit.ly/3thXqu0 #Engineering #Opportunities

mRNA is one of the most exciting fields in medical science today. There are many possibilities to target infectious diseases and life-threatening viruses using mRNA technology. Our expertise has the potential to shape the future of immunity medications. Check out this video to learn more, then search for opportunities on our careers site to help us make #AMeaningfulDifference. #WeAreLonzaMRNA #mRNA #Opportunities

Nuestras inversiones te ofrecen oportunidades de trabajo en un amplio abanico de sectores. Te invitamos a que veas nuestro video para saber más sobre tu futuro con nosotros y que presentes tu candidatura hoy: https://www.lonza.com/careers/job-search

Am Standort Visp gestalten wir die Zukunft für das Wallis sowie der gesamten Biopharma-Industrie mit. Durch neuste Technologie sowie Flexibilität in der Biopharma-Auftragsherstellung erfüllen wir individuelle Kundenbedürfnisse auf Höchststandard und ermöglichen damit Patienten ihr Leben zu verlängern oder sogar ihre Krankheiten zu heilen. Mit 300 Sonnenstunden im Jahr lädt unser Standort in Visp und das Wallis mit seinen Bergen und Wiesen zu schier grenzlosen Aktivitäten ein, wo Sie jedoch auch Kraft tanken und die Seele baumeln lassen können. Und falls es Sie doch in die urbanen Gebiete zieht, die grossen Schweizer Städte sowie Italien sind ebenfalls gleich um die Ecke. Interessiert? Bewerbe Dich noch heute unter https://www.lonza.com/careers/job-search und erlebe das Beste aus zwei Welten.

In our Small Molecules division at Lonza, we help customers develop, manufacture and innovate their small molecule medicines through our commitment to science, technology and delivery. We provide integrated drug substance and drug product services through our global site network across China, Europe and the US with a strong track record of being present throughout the product lifecycle. Our investment and growth are creating a range of opportunities and career paths. Small is our BIG thing. Join us and make a Meaningful Difference with us: https://www.lonza.com/careers/job-search?utm_medium=referral&utm_source=youtube&utm_campaign=evpl-videos&utm_content=SmallMolecules

Join us and make a Meaningful Difference: https://www.lonza.com/careers/job-search?q=*&pg=1&rows=100&job_posting_family_s=Manufacturing+Science+%26+Technology&utm_medium=referral&utm_source=youtube&utm_campaign=evpl-videos&utm_content=MSAT

Join us and make a Meaningful Difference: https://www.lonza.com/careers/job-search?q=*&pg=1&rows=100&job_posting_family_s=Engineering&utm_medium=referral&utm_source=youtube&utm_campaign=evpl-videos&utm_content=Engineering

Join us and make a Meaningful Difference: https://www.lonza.com/careers/job-search?q=*&rows=100&job_posting_family_s=Quality&utm_medium=referral&utm_source=youtube&utm_campaign=evpl-videos&utm_content=QC

Join us and make a Meaningful Difference: https://www.lonza.com/careers/job-search?q=*&rows=100&job_posting_family_s=Quality&utm_medium=referral&utm_source=youtube&utm_campaign=evpl-videos&utm_content=QA

Join us and make a Meaningful Difference: https://www.lonza.com/careers/job-search?q=*&rows=100&job_posting_family_s=Quality&utm_medium=referral&utm_source=youtube&utm_campaign=evpl-videos&utm_content=QualityOverall

Join us and make a Meaningful Difference: https://www.lonza.com/careers/job-search?q=*&pg=1&rows=100&job_posting_family_s=Manufacturing+Operations+%26+Production&utm_medium=referral&utm_source=youtube&utm_campaign=evpl-videos&utm_content=ManuOps

Our state-in-the-art facility in Bend, Oregon, is a Center of Excellence for bioavailability enhancement and drug delivery, which pioneered spray-dried dispersion technology. We support our clients throughout the entire lifecycle of their drug candidate, from preclinical and first in human to late-stage development and commercial production of drug product intermediates and finished drug products. With more than 400 employees, our team applies its talent to improve treatments spanning digestive issues, genetic disorders, cancer and Hepatitis C. And there is much more than the works alone, the local region offers an amazing outdoor lifestyle, and sunny days throughout much of the year. Join us and let's make together a Meaningful Difference: https://www.lonza.com/careers/job-search?q=*&rows=100&job_location_facet_sm=United+States%2c+Bend+(Oregon)&utm_medium=referral&utm_source=youtube&utm_campaign=evpl-videos&utm_content=Bend

Rooted in the Bay Area and close to innovation in vaccines and therapeutics, our 17,200 ft2 cGMP facilities at the Hayward site provide state-of-the-art, single-use manufacturing technology to support our customers with their clinical programs. Whether our customers are developing life-saving therapies for cancer or potential treatments for COVID-19, we can support them with world-class manufacturing and process excellence. There is a chance to work with upcoming biotech and established pharmaceutical companies and to the manufacturing technology needed to produce the potential blockbuster treatments of tomorrow. Join us and make a Meaningful Difference with us: https://www.lonza.com/careers/job-search?q=*&rows=100&job_location_facet_sm=United+States%2c+Hayward+(California)

In Switzerland’s breathtaking Valais region in the Heart of the Swiss Alps, Visp remains our largest site with thousands of experts and industry-leading facilities. This site is one of the most significant for R&D, development and manufacturing. Our services include pharmaceutical applications in mRNA, mammalian and microbial biopharmaceuticals, small molecules, highly potent APIs, peptides and bioconjugates including antibody-drug conjugates (ADCs). We innovate and we do it at speed: setting up new production lines for the mRNA drug substance manufacturing has taken a matter of months rather than years. When you join us, you will experience the best of both worlds: the chance to transform patient treatments through groundbreaking technology, while enjoying the Alpine lifestyle. Join us and make a Meaningful Difference with us: https://www.lonza.com/careers/job-search?q=*&rows=100&job_location_facet_sm=Switzerland%2c+Visp

We are more than 100 experts working across Process Development and Bioassay Services. We take the earliest of ideas, experiment, develop, test and grow. We develop systems and processes to create treatments and therapies that positively impact thousands of people. Join our team in Development Services: https://www.lonza.com/careers/job-search

Lonza’s Biologics division has built a highly-respected track record with an extensive contract development and manufacturing offering. In 2020 more than 5,000 experts across our global network provided services for more than 45 commercial large molecules and supported the development of more than 420 pre-clinical and clinical large molecules. Our team works across wide-ranging technologies, constantly developing new skills to find better solutions for our diverse customer base including tiny startups to big pharma. It is an exciting time for you to join as we invest significantly to meet growing demand for large-scale mammalian manufacturing, mRNA, COVID related projects and others. Join us and make a Meaningful Difference with us: https://www.lonza.com/careers/job-search

Christian Noti is a Team Leader for API Development Services and HPAPI Laboratory at Lonza’s site in Visp, Switzerland. His work is focused on expanding Lonza’s HPAPI business. Learn more about our “Meet the Experts” video series here: https://pharma.lonza.com/knowledge-center/meet-the-experts

Michael Grass is Head of Solid Form Services and Global Research and Development at Lonza’s site in Bend, Oregon. His work supports programs across Lonza’s Small Molecules Division & focuses on solid-form selection, stability, and materials science. Learn more about our “Meet the Experts” video series here: https://pharma.lonza.com/knowledge-center/meet-the-experts

Conrad Roten is a Group Leader for API Development Services at Lonza’s site in Visp, Switzerland. His work is focused on process development for small-molecule projects and highly potent active pharmaceutical ingredients (#HPAPIs) in all clinical phases. Learn more about our “Meet the Experts” video series here: https://pharma.lonza.com/knowledge-center/meet-the-experts

Andreas Sieber is a Scientific Expert in Solids in the Process Technology and Innovation Group at Lonza’s site in Visp, Switzerland. His work is focused on a number of areas including solvent-based crystallizations and wastewater treatment. Learn more about our “Meet the Experts” video series here: https://pharma.lonza.com/knowledge-center/meet-the-experts

David Lyon is a Senior Fellow in Global Research and Development at Lonza’s site in Bend, Oregon. His work is focused on internal and external collaborations for bioavailability enhancement technologies and inhalation. Learn more about our “Meet the Experts” video series here: https://pharma.lonza.com/knowledge-center/meet-the-experts

Deanna Mudie is a Principal Scientist in Research and Development at Lonza’s site in Bend Oregon. Her work focuses on bioavailability enhancement, developing dosage form platforms & in vitro dissolution methodologies to predict bioperformance. Learn more about our “Meet the Experts” video series here: https://pharma.lonza.com/knowledge-center/meet-the-experts

Jakob Bonde is Head of Regulatory Affairs of the Small Molecules division at Lonza’s site in Visp, Switzerland. His work is focused on advising our global customers on regulatory compliance and CMC documentation. Learn more about our “Meet the Experts” video series here: https://pharma.lonza.com/knowledge-center/meet-the-experts

Programme Management (PM) plays the vital role of taking customer projects through to commercialization. The team translates needs into plans, sets clear priorities, and anticipates change – collaborating with experts across our sites to simplify complexity. Lonza PM professionals are trusted partners to our customers, ensuring new ideas are turned into reality to enable a healthier world. Our PM careers come with a 360-degree view of the business and the opportunity to make Lonza stand out. Join our team and make a Meaningful Difference with us: https://www.lonza.com/careers/job-search?q=*&pg=1&rows=100&job_posting_family_s=Program+%26+Project+Management

Did you know that we are the 1st biologics contract manufacturer in Singapore? We offer you exposure to upcoming biotech and established pharmaceutical companies and to the manufacturing technology needed to produce the treatments of tomorrow. The work we do enables our customers to enhance the lives of thousands of patients around the world. Our global manufacturing network is recognized for its reliable, high-quality services, regulatory track record, global footprint, innovative technology platforms and extensive experience – we, in Singapore are proud to be part of this global network. Looking to make a Meaningful Difference? Join us: https://www.Lonza.com/SingaporeCareers

A short video highlight of what makes our dedicated cell & gene therapies site in the Netherlands so special.

Throughout the pandemic, the importance of virtual tools has dramatically increased. When it came to training Lonza employees on new manufacturing methods, global travel restrictions and COVID-19 safety measures presented a significant challenge: how can we virtually train Lonza employees to operate critical equipment efficiently and effectively? It quickly became apparent that innovative solutions were required to cope with the increasing demands for virtual training, especially in operations and clean-room facilities. In collaboration with our digital transformation team, realworld one, trainers and subject matter experts from Lonza, we created a virtual, safe training environment for our colleagues to learn how to confidently handle and use the equipment.

We want to be your partner and drive pioneering therapies to the market. We invest heavily in enabling technologies and building expertise to support development and commercialization of your innovative therapies. Our scientists and engineers have decades of development experience across a broad spectrum of cell types and technologies. This forms the backbone of an extensive service offering, providing you with tailored process and analytical development, GMP manufacturing and regulatory services.

Click here to watch the full video featuring our experts interviews: https://go2.lonza.com/CGT_PD_Video.html

Watch this video to learn how Lonza is helping to reshape the future of cancer care! We are contributing to an emerging class of medicines, called Antibody Drug Conjugates (ADCs), which deliver stronger therapeutic effects and contribute to a better quality of life for cancer patients. Manufacturing these complex bioconjugates is a delicate business but with the right team and technology, we can bring them to life. To learn more about our antibody-drug conjugate offerings visit https://www.lonza.com/custom-manufacturing/small-molecule-technologies/antibody-drug-conjugates-adcs.aspx

Lonza offers meaningful career experiences for interested talent! Via electronic screen, placed at a career fair in Basel, we asked candidates to join us for a spontaneous trip to Lonza in Visp (CH), located in the heart of the Swiss Alps. Those that followed our invite, gained insights into our career opportunities, networked with experts in their field of interest and participated in a site tour. Watch the video to see the highlights of the day. Would you be spontaneous enough to follow our invite? Look out for the Lonza electronic screen. With our career days, we make #AMeaningfulDifference. Visit our careers page: https://www.lonza.com/about-lonza/careers/working-at-lonza.aspx

We are here to make #AMeaningfulDifference. It is the foundation of the way we do business. Looking after our people, our customers, our planet is core to our purpose. A career at Lonza is more than a job. We do not just work in the life sciences industries, we are transforming them. What we do today is helping to create a healthier, happier world tomorrow. Visit our careers page: https://www.lonza.com/about-lonza/careers.aspx

We are here to make #AMeaningfulDifference. It is the foundation of the way we do business. Looking after our people, our customers, our planet is core to our purpose. A career at Lonza is more than a job. We do not just work in the life sciences industries, we are transforming them. What we do today is helping to create a healthier, happier world tomorrow. Visit our careers page: https://www.lonza.com/about-lonza/careers.aspx

What makes the Valais great for families? Watch our video to learn more about a completely new lifestyle for you and your family. Discover why living and working in the Alpine Valais region offers #TheBestofBothWorlds https://www.lonza.com/campaigns/careers-in-visp.aspx Find roles at: https://www.lonza.com/campaigns/careers-in-visp/ibex-solutions.aspx

Join Lonza Ibex™ in Visp to be part of a biotech revolution. See if there’s an opportunity for you at: https://www.lonza.com/campaigns/careers-in-visp/ibex-solutions.aspx

Looking for the right place to start your career? Join us at Lonza in Visp. Find roles at: https://www.lonza.com/campaigns/careers-in-visp/ibex-solutions.aspx

Want to work in a place where you’ll feel at home? You’ll find a warm welcome at Lonza in Visp. Discover why living and working in the Alpine Valais region offers #TheBestofBothWorlds: https://www.lonza.com/campaigns/careers-in-visp/live-in-the-valais.aspx Find roles at: https://www.lonza.com/campaigns/careers-in-visp/ibex-solutions.aspx

See why we’re so excited about our new Ibex™ Solutions facility. Lonza Visp offers a promising future for talented people all over the world. Visit our careers page to find available opportunities: https://www.lonza.com/campaigns/careers-in-visp/ibex-solutions.aspx

Looking for a balanced and active lifestyle? Then you’ll love living and working in the Valais, Switzerland. Discover why living and working in the Alpine Valais region offers #TheBestofBothWorlds: https://www.lonza.com/campaigns/careers-in-visp/live-in-the-valais.aspx Apply today: https://www.lonza.com/campaigns/careers-in-visp/ibex-solutions.aspx

Joining Ibex™ now is a once in a career opportunity. Don’t miss it! Ibex™ is a campus of five state-of-the-art manufacturing complexes that provides biopharma customers with agile capability from late discovery to clinical and commercial manufacturing. See current job opportunities at: https://www.lonza.com/campaigns/careers-in-visp/ibex-solutions.aspx

Joining us in Visp means changing more than your employer. Moving to our region will offer you a whole new lifestyle – relaxed, healthy, close to nature. To learn more about living and working in the Valais visit: https://www.lonza.com/campaigns/careers-in-visp/live-in-the-valais.aspx Find roles at: https://www.lonza.com/visp-careers